pilocarpine has been researched along with Xerostomia in 195 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
Xerostomia: Decreased salivary flow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate and compare the efficacy of pilocarpine and artificial saliva as symptomatic treatments for xerostomia and xerophthalmia in patients with SS." | 9.27 | Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial. ( Cifuentes, M; Del Barrio-Díaz, P; Vera-Kellet, C, 2018) |
| "This report presents the analysis of the RTOG 0537 multicenter randomized study that compared acupuncture-like transcutaneous stimulation (ALTENS) with pilocarpine (PC) for relieving radiation-induced xerostomia." | 9.20 | Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study. ( Berk, L; Cardinale, J; Deshmukh, S; Hodson, I; Matthiesen, CL; Nguyen-Tân, PF; Pugh, SL; Sagar, S; Singh, AK; Suh, J; Sultanem, K; Thakrar, H; Wong, RK; Wyatt, G; Yao, M; Yom, SS, 2015) |
| "Submandibular SGT procedure is superior to pilocarpine in management of radiation-induced xerostomia." | 9.14 | Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. ( Barnaby, P; Black, M; Butler, J; Ghosh, S; Harris, J; Hier, M; Jha, N; Kerr, P; Seikaly, H; Sultanem, K; Sutherland, D; Williams, D, 2009) |
| "The authors determined the efficacy and safety of oral pilocarpine tablet in symptomatic relief of post-radiation xerostomia in head and neck cancer patients." | 9.13 | Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Pattarasakulchai, T; Pukanhaphan, N; Sittitrai, P; Sukthomya, V; Sumitsawan, Y; Tharavichitkul, E; Traisatit, P, 2008) |
| " As genetic predisposition and ethnicity may alter the effectiveness of drug treatment, evaluation of the efficacy and safety of the secretagogue pilocarpine hydrochloride in the treatment of xerostomia in patients with SS in different populations is needed." | 9.12 | Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. ( Hsieh, SC; Lee, KL; Li, KJ; Lu, MC; Wu, CH; Yu, CL, 2006) |
| "The aim of this study was to quantify improvement in clinical symptoms and salivary function after treatment of post-radiation xerostomia with pilocarpine lozenges." | 9.12 | Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. ( Aromdee, C; Khunkitti, W; Laopaiboon, M; Pesee, M; Taweechaisupapong, S, 2006) |
| "A total number of 60 patients were randomized into the trial, but unfortunately only 39 patients were finally evaluated for xerostomia, 18 in the pilocarpine and 21 in the placebo group." | 9.10 | A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. ( Haddad, P; Karimi, M, 2002) |
| "To examine salivary function in patients with primary Sjögren's syndrome (SS) by assessing unstimulated and stimulated flows using 5 mg of pilocarpine in a 5% solution, in order to define their clinical usefulness in the evaluation of xerostomia in patients with primary SS as well as to identify those factors related to the increase in salivary flow after pilocarpine stimulation." | 9.10 | Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features. ( Caballero, O; Cervera, R; Ena, J; Font, J; García-Carrasco, M; Ingelmo, M; Pascual, E; Ramos-Casals, M; Rosas, J; Verdu, J, 2002) |
| " The aim of our study was to evaluate whether the sialogogue pilocarpine given during radiation therapy may reduce the severity of xerostomia and salivary dysfunction." | 9.09 | Pilocarpine in the prevention of postirradiation xerostomia. ( Borcić, V; Krajina, Z; Krpan, D; Lajtman, Z; Popović-Kovacić, J; Vincelj, J, 2000) |
| "The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia: (2) to correlate the response to dose/volume radiotherapy parameters." | 9.09 | Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. ( Alfonsi, M; Ardiet, JM; Baillet, F; Bensadoun, RJ; Bolla, M; Bourdin, S; Calais, G; Coche-Dequéant, B; Coscas, Y; Desprez, P; Horiot, JC; Lapeyre, M; Lipinski, F; Maral, J; Maulard-Durdux, C; Montbarbon, X; Pene, F; Schraub, S; Urbajtel, M; Vinke, J; Wibault, M, 2000) |
| "Pilocarpine hydrochloride administered during head and neck irradiation was evaluated for its ability to relieve xerostomia and its adverse effects." | 9.09 | Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. ( Phungrassami, T; Sangthawan, D; Watthanaarpornchai, S, 2001) |
| "Eighteen patients with xerostomia refractory to pilocarpine therapy after XRT for head and neck malignancy were offered acupuncture as palliation." | 9.09 | Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. ( Inouye, WS; Johnstone, PA; May, BC; Niemtzow, RC; Peng, YP, 2001) |
| "Pilocarpine hydrochloride administered in either a fixed-dose or in a dose-titration protocol three times a day for 12 weeks was evaluated for its ability to relieve symptoms of postradiation xerostomia and to improve saliva production." | 9.08 | Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. ( Gallagher, SC; Hafermann, MD; Iwamoto, R; Johnson, JT; LeVeque, FG; Muscoplat, C; Rieke, JW; Steiger, BW, 1995) |
| "Pilocarpine hydrochloride suspended in a candy-like pastille was evaluated as a topical treatment for radiation-induced xerostomia in head and neck cancer patients." | 9.08 | Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. ( Altman, JS; Buerki, RA; Elzinga, DJ; Gahbauer, RA; Hall, J; Hamlar, DD; Martin, MR; Schuller, DE; Staubus, AE, 1996) |
| "Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month multicenter maintenance study to evaluate the long-term safety and efficacy of oral pilocarpine for the treatment of radiation-induced xerostomia." | 9.08 | A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. ( Jacobs, CD; van der Pas, M, 1996) |
| "To retrospectively compare subjective postirradiation xerostomia scores of patients who received concomitant oral pilocarpine during radiotherapy for head and neck cancer and 3 months thereafter with those of similar cohorts who did not receive pilocarpine." | 9.08 | Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. ( Juillard, GF; Mark, RJ; Tran, LM; Zimmerman, RP, 1997) |
| "This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and pilocarpine hydrochloride (Salagen) in the management of xerostomia in patients with advanced cancer." | 9.08 | A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. ( Daniels, C; Davies, AN; Pugh, R; Sharma, K, 1998) |
| "Twenty patients with radiation-induced xerostomia were entered into a prospective randomized crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and a mouthwash containing pilocarpine (5 mg three times a day)." | 9.07 | A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. ( Davies, AN; Singer, J, 1994) |
| "We evaluated pilocarpine hydrochloride for the treatment of radiation-induced xerostomia, a common complication of irradiation of the head and neck." | 9.07 | Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. ( Ferretti, GA; Fox, PC; Gallagher, SC; Johnson, JT; Muscoplat, CC; Nethery, WJ; Ng, D; Valdez, IH, 1993) |
| " This study evaluated whether the sialogogue pilocarpine given during radiation therapy may reduce the severity of xerostomia and salivary dysfunction." | 9.07 | Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. ( Atkinson, JC; Fox, PC; Macynski, AA; Valdez, IH; Wolff, A, 1993) |
| "To determine the efficacy and safety of pilocarpine hydrochloride for symptomatic relief of postradiation xerostomia symptoms and for saliva production in patients with head and neck cancer." | 9.07 | A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. ( Gallagher, SC; LeVeque, FG; Montgomery, M; Muscoplat, CC; Potter, D; Rieke, JW; Steiger, BW; Zimmer, MB, 1993) |
| "Pilocarpine and placebo tablets were administered for 90 day periods in a double-blind, sequential crossover trial to 12 patients with postradiation xerostomia." | 9.06 | Effectiveness of pilocarpine in postradiation xerostomia. ( Daniels, TE; Greenspan, D, 1987) |
| "On the basis of the best available evidence, the results of this meta-analysis provide evidence that pilocarpine offers statistically significant clinical benefits for the symptomatic treatment of radiation-induced xerostomia in patients with head and neck cancer." | 8.93 | Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. ( Cheng, CQ; Li, J; Liu, L; Liu, YT; Wang, RN; Xu, H; Zhou, XK, 2016) |
| "To evaluate the efficacy of concomitant administration of pilocarpine on radiation-induced xerostomia in patients with head and neck cancers." | 8.93 | Is Pilocarpine Effective in Preventing Radiation-Induced Xerostomia? A Systematic Review and Meta-analysis. ( Hakim, SG; Liao, GQ; Ouyang, DQ; Ringash, J; Su, YX; Yang, WF, 2016) |
| "This review discusses the randomized trials available on the efficacy and tolerability of oral pilocarpine for the treatment of xerostomia." | 8.84 | Systemic pilocarpine for treatment of xerostomia. ( Berk, L, 2008) |
| "This article examines the use of pilocarpine hydrochloride for radiation-induced xerostomia in patients with head and neck cancer." | 8.80 | Pilocarpine for radiation-induced xerostomia in head and neck cancer. ( Hawthorne, M; Sullivan, K, 2000) |
| "To analyze the role of oral pilocarpine in the treatment of xerostomia of Sjogren's syndrome (SS)." | 8.80 | The use of oral pilocarpine in xerostomia and Sjögren's syndrome. ( Nusair, S; Rubinow, A, 1999) |
| "Pilocarpine is a cholinergic agonist which stimulates salivary secretion both in individuals with normal salivary gland function and in those with impaired salivary flow (xerostomia or oral dryness)." | 8.79 | Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. ( Faulds, D; Wiseman, LR, 1995) |
| "A 63-year-old man with pharyngeal cancer had been prescribed pilocarpine hydrochloride for xerostomia after concomitant chemoradiotherapy." | 7.91 | A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride. ( Fujii, T; Kashima, J; Kawasoe, K; Nishizawa, Y; Nitta, K; Ohta, A; Tonooka, A, 2019) |
| "A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD)." | 7.74 | Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). ( Agha-Hosseini, F; Ghavamzadeh, A; Ghavamzadeh, L; Mirzaii-Dizgah, I; Tohidast-Acrad, Z, 2007) |
| "The present study was performed to assess the effects of pilocarpine hydrochloride ((3S,4R)-3-ethyl-dihydro-4-[(1-methyl-1H-imidazole-5-yl)methyl]-2(3H)-furanone monohydrochloride, CAS 54-71-7) and cevimeline ((+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate, CAS 153504-70-2), muscarinic receptor agonists, on salivary secretion from the submandibular/sublingual (SM/SL) glands in normal rats and in rats with xerostomia induced by X-ray (15 Gy) irradiation." | 7.72 | Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. ( Asari, T; Kojima, M; Kusama, H; Maruyama, K; Omori, Y; Shibata, N, 2003) |
| " Oral pilocarpine (Salagen(R)), 30 mg/day, can ameliorate cGVHD-induced xerostomia and improve the flow rate from the major salivary glands." | 7.71 | The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. ( Nagler, A; Nagler, RM, 2001) |
| " In the present study, we investigated the prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by either single (15 Gy) or repeated (8." | 7.71 | Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats. ( Akahane, M; Asari, T; Hara, K; Komatsu, Y; Misawa, K, 2001) |
| " Because of concern about causing xerostomia with its attendant problems, pilocarpine hydrochloride, 5 mg orally three times daily, was initiated at the onset of radiotherapy." | 7.70 | The use of pilocarpine hydrochloride to prevent xerostomia in a child treated with high dose radiotherapy for nasopharynx carcinoma. ( Deutsch, M, 1998) |
| "This study was undertaken to determine whether standard salivary gland scintigraphy may be used for the objective assessment of salivary gland sialogogues, in particular oral pilocarpine, in the treatment of post-radiotherapy xerostomia." | 7.70 | Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? ( Allan, E; Collins, CD; Cooper, RA; Cowan, RA; Gupta, NK; Hillel, PG; Jeans, SP; Owens, SE; Roberts, JK; Slevin, NJ, 1999) |
| "To determine the prognostic value of a test using pilocarpine chloride to identify those patients with xerostomia who may achieve a long-term increase in SFR in response to acupuncture." | 7.70 | Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. ( Blom, M; Kopp, S; Lundeberg, T, 1999) |
| "Twenty-four patients with radiation-related xerostomia were treated with oral pilocarpine solution 6 mg t." | 7.68 | Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. ( Boström, P; Joensuu, H; Makkonen, T, 1993) |
| "Xerostomia has a devastating impact on oral function and quality of life in patients who receive radiation treatment for head and neck cancer." | 6.77 | Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer. ( Harris, J; Jha, N; Lam Tang, JA; Rieger, JM; Seikaly, H, 2012) |
| "Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal whole saliva production ≥0." | 6.77 | Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. ( Berk, L; Cardinale, F; James, JL; Lukaszczyk, B; Nguyen-Tân, PF; Sagar, S; Singh, AK; Wong, RK; Wyatt, G; Yeh, AM, 2012) |
| " Identically appearing placebo solution with the same dosing schedule and duration was used for the control subjects." | 6.67 | Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. ( Rhodus, NL; Schuh, MJ, 1991) |
| "Oral pilocarpine (PCP) to treat xerostomia produces systemic side effects, such as runny nose and lacrimation." | 5.72 | Topical Xerostomia Treatment with Hyaluronate Sheets Containing Pilocarpine. ( Furubayashi, T; Nakano, H; Okae, A; Sakane, T; Suzuki, K; Tanaka, A; Ueno, T; Yoneto, C; Yoneto, K, 2022) |
| "Pilocarpine is an accepted treatment for xerostomia, but limited research has been conducted on the oral, topical form." | 5.51 | Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial. ( Alaee, A; Azizi, A; Fard, MJK; Jafari, A; Jahandar, H; Motamed, B, 2022) |
| "Pilocarpine was scrutinized in terms of controlled release behavior." | 5.51 | Buccal adhesive chitosan conjugate comprising pilocarpine for xerostomia. ( Laffleur, F; Röttges, S, 2019) |
| " However, there is no drug that is safe and effective for the xerostomia that occurs in patients of this age group." | 5.36 | Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome. ( Kohno, Y; Kuwada, N; Nonaka, Y; Saito, K; Shimojo, N; Takei, S; Tomiita, M, 2010) |
| " pilocarpine for at least for 12 weeks unless they had experienced unacceptable adverse effects." | 5.35 | Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese. ( Asakage, T; Ebihara, Y; Igaki, H; Nakagawa, K; Nakamura, N; Nakao, K; Ohtomo, K; Sasano, N; Shiraishi, K; Terahara, A; Yamashita, H, 2009) |
| "Pilocarpine has been used as an ophthalmologic agent for decades; however, toxicity rarely has been reported in the medical literature." | 5.32 | Pilocarpine toxicity and the treatment of xerostomia. ( Greenberg, MI; Hendrickson, RG; Morocco, AP, 2004) |
| "(1) Dry mouth (xerostomia) is a frequent complication of radiation therapy for cancers of the ear nose and throat." | 5.31 | Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. ( , 2002) |
| "This investigation was carried out to try the application of pilocarpine hydrochloride (PC) solid dispersion as sustained release dosage form." | 5.30 | [Preparation and evaluation of solid dispersions of pilocarpine hydrochloride for alleviation of xerostomia]. ( Miyazaki, S; Oda, M; Ohno, K; Sato, M; Takada, M; Watanabe, S; Yagi, N, 1997) |
| "Pilocarpine HCl has been shown to stimulate parotid and submandibular gland salivary flow." | 5.30 | Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. ( Rhodus, NL, 1997) |
| "As pilocarpine hydrochloride has been shown to relieve xerostomia in other disease categories, we administered pilocarpine hydrochloride 30 mg/day to six cGVHD patients and measured their whole saliva, parotid and submandibular-sublingual flow rates in both resting and stimulated conditions." | 5.30 | Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. ( Nagler, A; Nagler, RM, 1999) |
| "Pilocarpine stimulus was characterized by a peak in amylase activity--regularly observed in the first 40-60 min--which was additive to the cholinergic amylase secretory response." | 5.28 | [Analysis of the effectiveness of pilocarpine in the management of xerostomia]. ( Blazsek, J; Kelemen, E; Zelles, T, 1990) |
| "To investigate and compare the efficacy of pilocarpine and artificial saliva as symptomatic treatments for xerostomia and xerophthalmia in patients with SS." | 5.27 | Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial. ( Cifuentes, M; Del Barrio-Díaz, P; Vera-Kellet, C, 2018) |
| "This report presents the analysis of the RTOG 0537 multicenter randomized study that compared acupuncture-like transcutaneous stimulation (ALTENS) with pilocarpine (PC) for relieving radiation-induced xerostomia." | 5.20 | Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study. ( Berk, L; Cardinale, J; Deshmukh, S; Hodson, I; Matthiesen, CL; Nguyen-Tân, PF; Pugh, SL; Sagar, S; Singh, AK; Suh, J; Sultanem, K; Thakrar, H; Wong, RK; Wyatt, G; Yao, M; Yom, SS, 2015) |
| "There is controversy concerning the effect of pilocarpine in the reversal of radio-induced xerostomia; however, the tests are usually performed at the end of radiotherapy." | 5.19 | Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. ( Araújo, M; DA Costa, LJ; Filho, MM; Gomes, DQ; Pimentel, MJ, 2014) |
| "Submandibular SGT procedure is superior to pilocarpine in management of radiation-induced xerostomia." | 5.14 | Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. ( Barnaby, P; Black, M; Butler, J; Ghosh, S; Harris, J; Hier, M; Jha, N; Kerr, P; Seikaly, H; Sultanem, K; Sutherland, D; Williams, D, 2009) |
| "The authors determined the efficacy and safety of oral pilocarpine tablet in symptomatic relief of post-radiation xerostomia in head and neck cancer patients." | 5.13 | Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Pattarasakulchai, T; Pukanhaphan, N; Sittitrai, P; Sukthomya, V; Sumitsawan, Y; Tharavichitkul, E; Traisatit, P, 2008) |
| "To investigate the effect of concomitant administration of pilocarpine during radiotherapy for head-and-neck squamous cell carcinoma (HNSCC) on postradiotherapy xerostomia." | 5.13 | Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. ( Burlage, FR; Coppes, RP; Kampinga, HH; Langendijk, JA; Roesink, JM; Stokman, MA; Terhaard, C; van Luijk, P; Vissink, A, 2008) |
| " As genetic predisposition and ethnicity may alter the effectiveness of drug treatment, evaluation of the efficacy and safety of the secretagogue pilocarpine hydrochloride in the treatment of xerostomia in patients with SS in different populations is needed." | 5.12 | Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. ( Hsieh, SC; Lee, KL; Li, KJ; Lu, MC; Wu, CH; Yu, CL, 2006) |
| "The aim of this study was to quantify improvement in clinical symptoms and salivary function after treatment of post-radiation xerostomia with pilocarpine lozenges." | 5.12 | Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. ( Aromdee, C; Khunkitti, W; Laopaiboon, M; Pesee, M; Taweechaisupapong, S, 2006) |
| "The efficacy of pilocarpine given during radiotherapy for head-neck cancer to reduce xerostomia was assessed." | 5.11 | Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. ( Black, M; Gornitsky, M; Hier, M; Katz, H; Shenouda, G; Sultanem, K; Velly, AM, 2004) |
| "To test the hypothesis that the use of oral pilocarpine during and after radiotherapy (RT) for head-and-neck cancer would reduce the symptoms of post-RT xerostomia." | 5.10 | A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. ( Aslanidis, J; Bayley, A; Cummings, BJ; Kim, J; Kroll, B; Liu, FF; Lockwood, G; Maxymiw, W; O'Sullivan, B; Payne, D; Ringash, J; Sprague, S; Waldron, J; Warde, P, 2002) |
| "A total number of 60 patients were randomized into the trial, but unfortunately only 39 patients were finally evaluated for xerostomia, 18 in the pilocarpine and 21 in the placebo group." | 5.10 | A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. ( Haddad, P; Karimi, M, 2002) |
| "To examine salivary function in patients with primary Sjögren's syndrome (SS) by assessing unstimulated and stimulated flows using 5 mg of pilocarpine in a 5% solution, in order to define their clinical usefulness in the evaluation of xerostomia in patients with primary SS as well as to identify those factors related to the increase in salivary flow after pilocarpine stimulation." | 5.10 | Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features. ( Caballero, O; Cervera, R; Ena, J; Font, J; García-Carrasco, M; Ingelmo, M; Pascual, E; Ramos-Casals, M; Rosas, J; Verdu, J, 2002) |
| " The aim of our study was to evaluate whether the sialogogue pilocarpine given during radiation therapy may reduce the severity of xerostomia and salivary dysfunction." | 5.09 | Pilocarpine in the prevention of postirradiation xerostomia. ( Borcić, V; Krajina, Z; Krpan, D; Lajtman, Z; Popović-Kovacić, J; Vincelj, J, 2000) |
| "The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia: (2) to correlate the response to dose/volume radiotherapy parameters." | 5.09 | Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. ( Alfonsi, M; Ardiet, JM; Baillet, F; Bensadoun, RJ; Bolla, M; Bourdin, S; Calais, G; Coche-Dequéant, B; Coscas, Y; Desprez, P; Horiot, JC; Lapeyre, M; Lipinski, F; Maral, J; Maulard-Durdux, C; Montbarbon, X; Pene, F; Schraub, S; Urbajtel, M; Vinke, J; Wibault, M, 2000) |
| "Pilocarpine hydrochloride administered during head and neck irradiation was evaluated for its ability to relieve xerostomia and its adverse effects." | 5.09 | Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. ( Phungrassami, T; Sangthawan, D; Watthanaarpornchai, S, 2001) |
| "Eighteen patients with xerostomia refractory to pilocarpine therapy after XRT for head and neck malignancy were offered acupuncture as palliation." | 5.09 | Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. ( Inouye, WS; Johnstone, PA; May, BC; Niemtzow, RC; Peng, YP, 2001) |
| "Pilocarpine hydrochloride administered in either a fixed-dose or in a dose-titration protocol three times a day for 12 weeks was evaluated for its ability to relieve symptoms of postradiation xerostomia and to improve saliva production." | 5.08 | Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. ( Gallagher, SC; Hafermann, MD; Iwamoto, R; Johnson, JT; LeVeque, FG; Muscoplat, C; Rieke, JW; Steiger, BW, 1995) |
| "Pilocarpine hydrochloride suspended in a candy-like pastille was evaluated as a topical treatment for radiation-induced xerostomia in head and neck cancer patients." | 5.08 | Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. ( Altman, JS; Buerki, RA; Elzinga, DJ; Gahbauer, RA; Hall, J; Hamlar, DD; Martin, MR; Schuller, DE; Staubus, AE, 1996) |
| "Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month multicenter maintenance study to evaluate the long-term safety and efficacy of oral pilocarpine for the treatment of radiation-induced xerostomia." | 5.08 | A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. ( Jacobs, CD; van der Pas, M, 1996) |
| "To retrospectively compare subjective postirradiation xerostomia scores of patients who received concomitant oral pilocarpine during radiotherapy for head and neck cancer and 3 months thereafter with those of similar cohorts who did not receive pilocarpine." | 5.08 | Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. ( Juillard, GF; Mark, RJ; Tran, LM; Zimmerman, RP, 1997) |
| "This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and pilocarpine hydrochloride (Salagen) in the management of xerostomia in patients with advanced cancer." | 5.08 | A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. ( Daniels, C; Davies, AN; Pugh, R; Sharma, K, 1998) |
| "Twenty patients with radiation-induced xerostomia were entered into a prospective randomized crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and a mouthwash containing pilocarpine (5 mg three times a day)." | 5.07 | A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. ( Davies, AN; Singer, J, 1994) |
| "We evaluated pilocarpine hydrochloride for the treatment of radiation-induced xerostomia, a common complication of irradiation of the head and neck." | 5.07 | Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. ( Ferretti, GA; Fox, PC; Gallagher, SC; Johnson, JT; Muscoplat, CC; Nethery, WJ; Ng, D; Valdez, IH, 1993) |
| " This study evaluated whether the sialogogue pilocarpine given during radiation therapy may reduce the severity of xerostomia and salivary dysfunction." | 5.07 | Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. ( Atkinson, JC; Fox, PC; Macynski, AA; Valdez, IH; Wolff, A, 1993) |
| "To determine the efficacy and safety of pilocarpine hydrochloride for symptomatic relief of postradiation xerostomia symptoms and for saliva production in patients with head and neck cancer." | 5.07 | A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. ( Gallagher, SC; LeVeque, FG; Montgomery, M; Muscoplat, CC; Potter, D; Rieke, JW; Steiger, BW; Zimmer, MB, 1993) |
| "Pilocarpine and placebo tablets were administered for 90 day periods in a double-blind, sequential crossover trial to 12 patients with postradiation xerostomia." | 5.06 | Effectiveness of pilocarpine in postradiation xerostomia. ( Daniels, TE; Greenspan, D, 1987) |
| "A MEDLINE/PubMed search was conducted using the terms "Xerostomia" AND, "Saliva Artificial" OR, "Citric Acid," "Malic Acid," "Chewing Gum," "Acupuncture" OR, "Pilocarpine" OR, "Bethanechol" OR, "Cevimeline" OR, "Hyperbaric Oxygen Therapy" OR, "Stem Cell Therapy" OR "Genetic Therapy" and their Mesh Terms." | 4.98 | Salivary hypofunction: An update on therapeutic strategies. ( Cherubini, K; Figueiredo, MAZ; Medella-Junior, FAC; Salum, FG, 2018) |
| "On the basis of the best available evidence, the results of this meta-analysis provide evidence that pilocarpine offers statistically significant clinical benefits for the symptomatic treatment of radiation-induced xerostomia in patients with head and neck cancer." | 4.93 | Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. ( Cheng, CQ; Li, J; Liu, L; Liu, YT; Wang, RN; Xu, H; Zhou, XK, 2016) |
| "To evaluate the efficacy of concomitant administration of pilocarpine on radiation-induced xerostomia in patients with head and neck cancers." | 4.93 | Is Pilocarpine Effective in Preventing Radiation-Induced Xerostomia? A Systematic Review and Meta-analysis. ( Hakim, SG; Liao, GQ; Ouyang, DQ; Ringash, J; Su, YX; Yang, WF, 2016) |
| "There is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced xerostomia." | 4.91 | Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. ( Davies, AN; Thompson, J, 2015) |
| "This review discusses the randomized trials available on the efficacy and tolerability of oral pilocarpine for the treatment of xerostomia." | 4.84 | Systemic pilocarpine for treatment of xerostomia. ( Berk, L, 2008) |
| " From studies published 2002 to 2005, 15 were identified as high-quality studies and were used to support management recommendations: pilocarpine and cevimeline are recommended for treating hyposalivation and xerostomia in primary and secondary Sjögren's syndrome (SS)." | 4.84 | Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. ( Brennan, MT; Carrozzo, M; Daniels, T; Fox, PC; Fujibayashi, T; Gandera, B; Jonsson, R; Lockhart, PB; Navazesh, M; Rhodus, NL; Schiødt, M; Sollecito, TP; von Bültzingslöwen, I; Wray, D, 2007) |
| "This article examines the use of pilocarpine hydrochloride for radiation-induced xerostomia in patients with head and neck cancer." | 4.80 | Pilocarpine for radiation-induced xerostomia in head and neck cancer. ( Hawthorne, M; Sullivan, K, 2000) |
| "To analyze the role of oral pilocarpine in the treatment of xerostomia of Sjogren's syndrome (SS)." | 4.80 | The use of oral pilocarpine in xerostomia and Sjögren's syndrome. ( Nusair, S; Rubinow, A, 1999) |
| "Pilocarpine is a cholinergic agonist which stimulates salivary secretion both in individuals with normal salivary gland function and in those with impaired salivary flow (xerostomia or oral dryness)." | 4.79 | Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. ( Faulds, D; Wiseman, LR, 1995) |
| "A 63-year-old man with pharyngeal cancer had been prescribed pilocarpine hydrochloride for xerostomia after concomitant chemoradiotherapy." | 3.91 | A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride. ( Fujii, T; Kashima, J; Kawasoe, K; Nishizawa, Y; Nitta, K; Ohta, A; Tonooka, A, 2019) |
| "The periodontitis model showed significant reductions in the weight of the bilateral major salivary glands and pilocarpine-induced salivary secretion." | 3.80 | Changes of salivary functions in experimental periodontitis model rats. ( Hitomi, S; Inenaga, K; Masuda, W; Matsuo, K; Nakamura-Kiyama, M; Nakashima, K; Ono, K; Usui, M; Yokota, M, 2014) |
| " Using rats, we examined the muscarinic receptor subtype mediating pilocarpine-induced parotid salivary secretion and the contributions of ion transporter systems (effluxes of K+ and Cl(-)) and aquaporin-5 (AQP5) translocation to this response in parotid glands in irradiated-induced xerostomia." | 3.75 | Salivation triggered by pilocarpine involves aquaporin-5 in normal rats but not in irradiated rats. ( Asari, T; Kusama, H; Maruyama, K, 2009) |
| "A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD)." | 3.74 | Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). ( Agha-Hosseini, F; Ghavamzadeh, A; Ghavamzadeh, L; Mirzaii-Dizgah, I; Tohidast-Acrad, Z, 2007) |
| "Byakko-ka-ninjin-to (BN) is a Kampo medicine (traditional Japanese medicine) that is frequently used to treat xerostomia, which is also a side effect of anticholinergic agents such as oxybutynin and propiverine widely used for the treatment of patients with urinary incontinence or frequency." | 3.73 | Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats. ( Aburada, M; Goto, K; Hattori, N; Ichiki, H; Iizuka, A; Ishige, A; Sakaguchi, M; Takeda, S; Yamamoto, M; Yamamoto, T; Yasuda, M, 2005) |
| "The present study was performed to assess the effects of pilocarpine hydrochloride ((3S,4R)-3-ethyl-dihydro-4-[(1-methyl-1H-imidazole-5-yl)methyl]-2(3H)-furanone monohydrochloride, CAS 54-71-7) and cevimeline ((+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate, CAS 153504-70-2), muscarinic receptor agonists, on salivary secretion from the submandibular/sublingual (SM/SL) glands in normal rats and in rats with xerostomia induced by X-ray (15 Gy) irradiation." | 3.72 | Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. ( Asari, T; Kojima, M; Kusama, H; Maruyama, K; Omori, Y; Shibata, N, 2003) |
| "Pilocarpine therapy is useful to improve xerostomia and xerophthalmia in SS patients with moderate and severe glandular involvement." | 3.72 | [Usefulness of oral pilocarpin therapy in the treatment of xerostomia and xerophthalmia in patients with primary Sjögren's syndrome]. ( Bosch, JA; Fonollosa, V; Selva, A; Simeón, CP; Solans, R; Vilardell, M, 2004) |
| " Oral pilocarpine (Salagen(R)), 30 mg/day, can ameliorate cGVHD-induced xerostomia and improve the flow rate from the major salivary glands." | 3.71 | The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. ( Nagler, A; Nagler, RM, 2001) |
| " In the present study, we investigated the prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by either single (15 Gy) or repeated (8." | 3.71 | Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats. ( Akahane, M; Asari, T; Hara, K; Komatsu, Y; Misawa, K, 2001) |
| " Because of concern about causing xerostomia with its attendant problems, pilocarpine hydrochloride, 5 mg orally three times daily, was initiated at the onset of radiotherapy." | 3.70 | The use of pilocarpine hydrochloride to prevent xerostomia in a child treated with high dose radiotherapy for nasopharynx carcinoma. ( Deutsch, M, 1998) |
| "This study was undertaken to determine whether standard salivary gland scintigraphy may be used for the objective assessment of salivary gland sialogogues, in particular oral pilocarpine, in the treatment of post-radiotherapy xerostomia." | 3.70 | Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? ( Allan, E; Collins, CD; Cooper, RA; Cowan, RA; Gupta, NK; Hillel, PG; Jeans, SP; Owens, SE; Roberts, JK; Slevin, NJ, 1999) |
| "To determine the prognostic value of a test using pilocarpine chloride to identify those patients with xerostomia who may achieve a long-term increase in SFR in response to acupuncture." | 3.70 | Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. ( Blom, M; Kopp, S; Lundeberg, T, 1999) |
| "Pilocarpine is used orally to treat xerostomia but patients vary widely in their response and ability to tolerate this drug." | 3.69 | Serum pilocarpine esterase activity and response to oral pilocarpine. ( Aromdee, C; Fawcett, JP; Ferguson, MM; Ledger, R, 1996) |
| "Twenty-four patients with radiation-related xerostomia were treated with oral pilocarpine solution 6 mg t." | 3.68 | Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. ( Boström, P; Joensuu, H; Makkonen, T, 1993) |
| "Oral doses of pilocarpine increase salivary flow rates in patients afflicted with xerostomia (dry mouth)." | 3.68 | Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. ( Kramer, PA; Tanzer, JM; Weaver, ML, 1992) |
| "We enrolled patients with overactive bladder symptoms in a multicenter, randomized, double-blind, parallel, active control study." | 2.90 | Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder. ( Choo, MS; Kim, HG; Kim, JH; Kim, KH; Kim, SO; Kim, SW; Ko, KJ; Lee, JZ; Lee, KS; Min, KS; Oh, SJ; Seo, JT, 2019) |
| "Pilocarpine is a cholinergic agent that promotes salivation." | 2.80 | Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study. ( Agar, M; Carmont, SA; Currow, D; Good, P; Hardy, J; Mitchell, GK; Nikles, J; Schluter, PJ; Senior, H; Vora, R, 2015) |
| "Xerostomia has a devastating impact on oral function and quality of life in patients who receive radiation treatment for head and neck cancer." | 2.77 | Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer. ( Harris, J; Jha, N; Lam Tang, JA; Rieger, JM; Seikaly, H, 2012) |
| "Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal whole saliva production ≥0." | 2.77 | Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. ( Berk, L; Cardinale, F; James, JL; Lukaszczyk, B; Nguyen-Tân, PF; Sagar, S; Singh, AK; Wong, RK; Wyatt, G; Yeh, AM, 2012) |
| "Pilocarpine has been approved for post-radiation xerostomia, and the effect of its use during radiation therapy on salivary flow, xerostomia, mucositis, and quality of life (QOL) was assessed in a phase III study conducted by the Radiation Therapy Oncology Group (RTOG 97-09)." | 2.72 | Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. ( Brachman, D; Foote, R; Hodson, DI; Lee, N; LeVeque, F; Meredith, R; Scarantino, C; Schulsinger, A; Swann, RS; White, R, 2006) |
| "D." | 2.71 | Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study. ( Chambers, MS; Gallagher, SC; Keene, HJ; Lemon, JC; Martin, CG; Martin, JW; Toth, BB, 2005) |
| "Xerostomia was measured on a linear analog scale." | 2.71 | Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. ( Cummings, B; Lockwood, G; O'Sullivan, B; Ringash, J; Waldron, J; Warde, P, 2005) |
| "Patients with head and neck cancers can develop salivary hypofunction after radiotherapy." | 2.70 | Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours. ( Ferre, J; Fuster, D; Lomeña, F; Martin, F; Mateos, JJ; Navalpotro, B; Ortega, M; Pavia, J; Pons, F; Rovirosa, A; Setoain, X, 2001) |
| " Identically appearing placebo solution with the same dosing schedule and duration was used for the control subjects." | 2.67 | Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. ( Rhodus, NL; Schuh, MJ, 1991) |
| "Dry mouth (xerostomia) is one of the commonest symptoms in cancer patients and can adversely affect quality of life." | 2.52 | Systematic literature review: xerostomia in advanced cancer patients. ( Adkinson, L; Daniel, S; Fleming, M; Hanchanale, S; Oxberry, SG, 2015) |
| "We undermitted the patient the dental treatment of Sjogren's syndrome." | 2.47 | Scleroderma and CREST syndrome: a case report in dentistry. ( Baldoni, M; Bussolati, A; Lauritano, D; Leonida, A, 2011) |
| "Radiation induced xerostomia is a frequent consequence of radiotherapy (RT) for head-neck cancer (HNC) patients, when parotid glands are included in the radiation fields." | 2.43 | Preventing radiation induced xerostomia. ( Danielidis, V; Koukourakis, MI, 2005) |
| "Xerostomia is a common symptom in the elderly population." | 2.43 | Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. ( Al-Hashimi, I, 2005) |
| "Xerostomia is a permanent and devastating sequela of head and neck irradiation, and its consequences are numerous." | 2.43 | Management of xerostomia related to radiotherapy for head and neck cancer. ( Johnstone, PA; Kahn, ST, 2005) |
| "Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients." | 2.43 | Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006) |
| "Head and neck cancer is becoming a more recognizable pathology to the general population and dentists." | 2.43 | Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia. ( Chai, WL; Ngeow, WC; Rahman, RA; Ramli, R, 2006) |
| "Xerostomia is one of the most severe symptoms that patients experience and may become a lifelong problem." | 2.42 | Radiation-induced xerostomia: how dry is your patient? ( Bruce, SD, 2004) |
| "The causes of xerostomia are numerous, of which the principal are, drug or radiation induced xerostomia and primary an secondary Sjögren's syndrome." | 2.41 | [Dry mouth]. ( Liozon, E; Soria, P; Vidal, E, 2001) |
| "Numerous regimens treat symptoms of xerostomia and associated caries and mucositis." | 2.40 | Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. ( Garg, AK; Malo, M, 1997) |
| "Oral pilocarpine (PCP) to treat xerostomia produces systemic side effects, such as runny nose and lacrimation." | 1.72 | Topical Xerostomia Treatment with Hyaluronate Sheets Containing Pilocarpine. ( Furubayashi, T; Nakano, H; Okae, A; Sakane, T; Suzuki, K; Tanaka, A; Ueno, T; Yoneto, C; Yoneto, K, 2022) |
| " SjS is a relatively rare immune-related adverse event that might sometimes be overlooked." | 1.56 | Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer. ( Furuta, Y; Higashi, T; Miyamoto, H; Nagaoka, K; Naito, H; Nakayama, H; Naoe, H; Tanaka, M; Yoshida, R, 2020) |
| " The aim of this investigation was to retrospectively run a head-to-head comparison for their effectiveness and frequency of adverse effects in patients with hyposalivation." | 1.51 | Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation. ( Cimmino, J; Farag, AM; Holliday, C; Papas, A; Roomian, T, 2019) |
| "Pilocarpine was scrutinized in terms of controlled release behavior." | 1.51 | Buccal adhesive chitosan conjugate comprising pilocarpine for xerostomia. ( Laffleur, F; Röttges, S, 2019) |
| "Hyposalivation is commonly observed in the autoimmune reaction of Sjögren's syndrome or following radiation injury to the major salivary glands." | 1.48 | Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation. ( Benoit, DSW; Hansen, ME; Newlands, SD; Ovitt, CE; Schmale, IL; Varghese, JJ, 2018) |
| "Early detection and treatment of hyperglycemia and hyposalivation may provide a useful strategy for preventing the dental complications of diabetes and promoting oral health in this population." | 1.38 | Hyperglycemia and xerostomia are key determinants of tooth decay in type 1 diabetic mice. ( Abboud-Werner, S; Chun, YH; Fajardo, R; Harris, SE; Horn, D; Jorgensen, J; Macdougall, M; Mohan, S; Yeh, CK, 2012) |
| " However, there is no drug that is safe and effective for the xerostomia that occurs in patients of this age group." | 1.36 | Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome. ( Kohno, Y; Kuwada, N; Nonaka, Y; Saito, K; Shimojo, N; Takei, S; Tomiita, M, 2010) |
| " pilocarpine for at least for 12 weeks unless they had experienced unacceptable adverse effects." | 1.35 | Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese. ( Asakage, T; Ebihara, Y; Igaki, H; Nakagawa, K; Nakamura, N; Nakao, K; Ohtomo, K; Sasano, N; Shiraishi, K; Terahara, A; Yamashita, H, 2009) |
| "Pilocarpine pre-treated rats, protection of parotid gland function was seen in the early-intermediate phase (0-120 days) after 15 Gy and in the late phase (>120 days) after 10 and 15 Gy." | 1.35 | Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment. ( Burlage, FR; Coppes, RP; Faber, H; Kampinga, HH; Langendijk, JA; Roesink, JM; Vissink, A, 2008) |
| "Treatment with pilocarpine hydrochloride tablets may improve saliva secretion in patients taking xerogenic medications and/or suffering from metabolic sialosis expanding the beneficial potential of this sialogogue." | 1.34 | Pilocarpine treatment in a mixed cohort of xerostomic patients. ( Aframian, DJ; Helcer, M; Livni, D; Markitziu, A; Nadler, C; Robinson, SD, 2007) |
| "Pilocarpine hydrochloride was shown to have some beneficial effect on quality of life of these patients." | 1.34 | Prevention of oral and salivary gland impairment in irradiated adolescent patients with head and neck cancer: a suggested protocol. ( Aframian, DJ; Davidovich, E; Peretz, B, 2007) |
| "Treatment with pilocarpine hydrochloride may be beneficial in the case of impaired salivary function in patients treated with radioiodine." | 1.33 | Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. ( Aframian, DJ; Helcer, M; Livni, D; Markitziu, A, 2006) |
| "Presently, treatments for xerostomia only target symptoms, as an active therapy method has not been established." | 1.33 | Transplantation of vascularized submandibular gland in dogs. ( Hamaguchi, M; Kogo, M; Tanaka Isomura, E; Yamamoto, YE; Yoshitomi, K, 2006) |
| "Oral pilocarpine was able to reduce and normalize the elevated levels of Na, Mg, TP, Alb, EGF, IgG, and IgA salivary concentrations at both resting and stimulated conditions." | 1.32 | Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease--a prolonged study. ( Nagler, A; Nagler, RM, 2003) |
| "Pilocarpine has been used as an ophthalmologic agent for decades; however, toxicity rarely has been reported in the medical literature." | 1.32 | Pilocarpine toxicity and the treatment of xerostomia. ( Greenberg, MI; Hendrickson, RG; Morocco, AP, 2004) |
| "(1) Dry mouth (xerostomia) is a frequent complication of radiation therapy for cancers of the ear nose and throat." | 1.31 | Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. ( , 2002) |
| "This investigation was carried out to try the application of pilocarpine hydrochloride (PC) solid dispersion as sustained release dosage form." | 1.30 | [Preparation and evaluation of solid dispersions of pilocarpine hydrochloride for alleviation of xerostomia]. ( Miyazaki, S; Oda, M; Ohno, K; Sato, M; Takada, M; Watanabe, S; Yagi, N, 1997) |
| "Pilocarpine HCl has been shown to stimulate parotid and submandibular gland salivary flow." | 1.30 | Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. ( Rhodus, NL, 1997) |
| "As pilocarpine hydrochloride has been shown to relieve xerostomia in other disease categories, we administered pilocarpine hydrochloride 30 mg/day to six cGVHD patients and measured their whole saliva, parotid and submandibular-sublingual flow rates in both resting and stimulated conditions." | 1.30 | Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. ( Nagler, A; Nagler, RM, 1999) |
| "Pilocarpine was buccally absorbed at a constant rate of 72." | 1.28 | Salivary flow induction by buccal permucosal pilocarpine in anesthetized beagle dogs. ( Kramer, PA; Tanzer, JM; Weaver, ML, 1992) |
| "Pilocarpine stimulus was characterized by a peak in amylase activity--regularly observed in the first 40-60 min--which was additive to the cholinergic amylase secretory response." | 1.28 | [Analysis of the effectiveness of pilocarpine in the management of xerostomia]. ( Blazsek, J; Kelemen, E; Zelles, T, 1990) |
| "Drug induced xerostomia is not uncommon particularly among the aging." | 1.28 | Drug-induced xerostomia. ( Butt, GM, 1991) |
| "Xerostomia is a common complication of radiation therapy to the head and neck." | 1.28 | Oral complications of cancer therapies. Management of salivary dysfunction. ( Greenspan, D, 1990) |
| "Dental Caries are an uncommon, but significant side effect of the tricyclic antidepressants and other anticholinergic psychoactive drugs." | 1.26 | Rampant dental caries in the treatment of depression. ( Bassuk, E; Schoonover, S, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (8.21) | 18.7374 |
| 1990's | 55 (28.21) | 18.2507 |
| 2000's | 79 (40.51) | 29.6817 |
| 2010's | 39 (20.00) | 24.3611 |
| 2020's | 6 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, A | 1 |
| Nakano, H | 1 |
| Yoneto, K | 1 |
| Yoneto, C | 1 |
| Furubayashi, T | 1 |
| Suzuki, K | 1 |
| Okae, A | 1 |
| Ueno, T | 1 |
| Sakane, T | 1 |
| Motamed, B | 3 |
| Alaee, A | 3 |
| Azizi, A | 3 |
| Jahandar, H | 3 |
| Fard, MJK | 3 |
| Jafari, A | 3 |
| Nguyen, TV | 1 |
| Chiu, KC | 1 |
| Shih, YH | 1 |
| Liu, CJ | 1 |
| Bao Quach, TV | 1 |
| Hsia, SM | 1 |
| Chen, YH | 1 |
| Shieh, TM | 1 |
| van der Meulen, AI | 1 |
| Neis, EPJG | 1 |
| de Nijs, EJM | 1 |
| Coenegracht, BJEG | 1 |
| Stoppelenburg, A | 1 |
| van den Beuken-van Everdingen, MHJ | 2 |
| van der Linden, YM | 1 |
| Farag, AM | 1 |
| Holliday, C | 1 |
| Cimmino, J | 1 |
| Roomian, T | 1 |
| Papas, A | 1 |
| Higashi, T | 1 |
| Miyamoto, H | 1 |
| Yoshida, R | 1 |
| Furuta, Y | 1 |
| Nagaoka, K | 1 |
| Naoe, H | 1 |
| Naito, H | 1 |
| Nakayama, H | 1 |
| Tanaka, M | 1 |
| Theunissen, M | 1 |
| Rideaux-Seferina, S | 1 |
| Magdelijns, FJ | 1 |
| Janssen, DJA | 1 |
| Riley, P | 1 |
| Glenny, AM | 1 |
| Hua, F | 1 |
| Worthington, HV | 1 |
| Barbe, AG | 1 |
| Shaalan, A | 1 |
| Carpenter, G | 1 |
| Proctor, G | 1 |
| Malallah, OS | 1 |
| Garcia, CMA | 1 |
| Proctor, GB | 1 |
| Forbes, B | 1 |
| Royall, PG | 1 |
| Cifuentes, M | 1 |
| Del Barrio-Díaz, P | 1 |
| Vera-Kellet, C | 1 |
| Varghese, JJ | 1 |
| Schmale, IL | 1 |
| Hansen, ME | 1 |
| Newlands, SD | 1 |
| Benoit, DSW | 1 |
| Ovitt, CE | 1 |
| Salum, FG | 1 |
| Medella-Junior, FAC | 1 |
| Figueiredo, MAZ | 1 |
| Cherubini, K | 1 |
| Al Hamad, A | 1 |
| Lodi, G | 1 |
| Porter, S | 1 |
| Fedele, S | 1 |
| Mercadante, V | 1 |
| Ko, KJ | 1 |
| Kim, KH | 1 |
| Kim, SW | 1 |
| Kim, SO | 1 |
| Seo, JT | 1 |
| Choo, MS | 1 |
| Lee, JZ | 1 |
| Oh, SJ | 1 |
| Kim, HG | 1 |
| Min, KS | 1 |
| Kim, JH | 2 |
| Lee, KS | 1 |
| Fujii, T | 1 |
| Kawasoe, K | 1 |
| Nishizawa, Y | 1 |
| Kashima, J | 1 |
| Tonooka, A | 1 |
| Ohta, A | 1 |
| Nitta, K | 1 |
| Laffleur, F | 1 |
| Röttges, S | 1 |
| Loeber, D | 2 |
| Aframian, DJ | 4 |
| Nahlieli, O | 1 |
| Knopf, A | 1 |
| Lukach, L | 1 |
| Qawasmeh, N | 1 |
| Nadler, C | 2 |
| López-López, J | 1 |
| Jané Salas, E | 1 |
| Chimenos Küstner, E | 1 |
| Ogawa, M | 1 |
| Oshima, M | 1 |
| Imamura, A | 1 |
| Sekine, Y | 1 |
| Ishida, K | 1 |
| Yamashita, K | 1 |
| Nakajima, K | 1 |
| Hirayama, M | 1 |
| Tachikawa, T | 1 |
| Tsuji, T | 1 |
| Nakamura-Kiyama, M | 1 |
| Ono, K | 1 |
| Masuda, W | 1 |
| Hitomi, S | 1 |
| Matsuo, K | 1 |
| Usui, M | 1 |
| Nakashima, K | 1 |
| Yokota, M | 1 |
| Inenaga, K | 1 |
| Ahn, HJ | 1 |
| Choi, JH | 1 |
| Jung, DW | 1 |
| Kwon, JS | 1 |
| Pimentel, MJ | 1 |
| Filho, MM | 1 |
| Araújo, M | 1 |
| Gomes, DQ | 1 |
| DA Costa, LJ | 1 |
| Sidhu, P | 1 |
| Hanchanale, S | 1 |
| Adkinson, L | 1 |
| Daniel, S | 1 |
| Fleming, M | 1 |
| Oxberry, SG | 1 |
| Wong, RK | 3 |
| Deshmukh, S | 1 |
| Wyatt, G | 2 |
| Sagar, S | 2 |
| Singh, AK | 2 |
| Sultanem, K | 3 |
| Nguyen-Tân, PF | 2 |
| Yom, SS | 1 |
| Cardinale, J | 1 |
| Yao, M | 1 |
| Hodson, I | 1 |
| Matthiesen, CL | 1 |
| Suh, J | 1 |
| Thakrar, H | 1 |
| Pugh, SL | 1 |
| Berk, L | 3 |
| Nikles, J | 1 |
| Mitchell, GK | 1 |
| Hardy, J | 1 |
| Agar, M | 1 |
| Senior, H | 1 |
| Carmont, SA | 1 |
| Schluter, PJ | 1 |
| Good, P | 1 |
| Vora, R | 1 |
| Currow, D | 1 |
| Takagi, Y | 1 |
| Sumi, M | 1 |
| Nakamura, H | 1 |
| Sato, S | 1 |
| Kawakami, A | 1 |
| Nakamura, T | 1 |
| Davies, AN | 3 |
| Thompson, J | 1 |
| Cheng, CQ | 1 |
| Xu, H | 1 |
| Liu, L | 1 |
| Wang, RN | 1 |
| Liu, YT | 1 |
| Li, J | 1 |
| Zhou, XK | 1 |
| Yang, WF | 1 |
| Liao, GQ | 1 |
| Hakim, SG | 1 |
| Ouyang, DQ | 1 |
| Ringash, J | 3 |
| Su, YX | 1 |
| Spivakovsky, S | 1 |
| Spivakovsky, Y | 1 |
| Nakamura, N | 1 |
| Sasano, N | 1 |
| Yamashita, H | 1 |
| Igaki, H | 1 |
| Shiraishi, K | 1 |
| Terahara, A | 1 |
| Asakage, T | 1 |
| Nakao, K | 1 |
| Ebihara, Y | 1 |
| Ohtomo, K | 1 |
| Nakagawa, K | 1 |
| Dave, SJ | 1 |
| Jorkjend, L | 1 |
| Bergenholtz, A | 1 |
| Johansson, AK | 1 |
| Johansson, A | 1 |
| Chitapanarux, I | 1 |
| Kamnerdsupaphon, P | 1 |
| Tharavichitkul, E | 1 |
| Sumitsawan, Y | 1 |
| Sittitrai, P | 1 |
| Pattarasakulchai, T | 1 |
| Lorvidhaya, V | 1 |
| Sukthomya, V | 1 |
| Pukanhaphan, N | 1 |
| Traisatit, P | 1 |
| Taubert, M | 1 |
| Davies, EM | 1 |
| Back, I | 1 |
| Gallego, L | 1 |
| Junquera, L | 1 |
| Cuesta, P | 1 |
| Rosado, P | 1 |
| Jha, N | 2 |
| Seikaly, H | 2 |
| Harris, J | 2 |
| Williams, D | 1 |
| Hier, M | 2 |
| Ghosh, S | 1 |
| Black, M | 2 |
| Butler, J | 1 |
| Sutherland, D | 1 |
| Kerr, P | 1 |
| Barnaby, P | 1 |
| Asari, T | 3 |
| Maruyama, K | 3 |
| Kusama, H | 2 |
| Visvanathan, V | 1 |
| Nix, P | 1 |
| Satoh, K | 2 |
| Narita, T | 2 |
| Matsui-Inohara, H | 1 |
| Ito, T | 2 |
| Senpuku, H | 2 |
| Sugiya, H | 2 |
| Sagar, SM | 1 |
| Chen, BJ | 1 |
| Yi, GY | 1 |
| Cook, R | 1 |
| Passafaro, D | 1 |
| Reina, S | 1 |
| Sterin-Borda, L | 1 |
| Borda, E | 1 |
| Tomiita, M | 1 |
| Takei, S | 1 |
| Kuwada, N | 1 |
| Nonaka, Y | 1 |
| Saito, K | 1 |
| Shimojo, N | 1 |
| Kohno, Y | 1 |
| Looström, H | 1 |
| Akerman, S | 2 |
| Ericson, D | 2 |
| Tobin, G | 2 |
| Götrick, B | 2 |
| Rieger, JM | 1 |
| Lam Tang, JA | 1 |
| Lauritano, D | 1 |
| Bussolati, A | 1 |
| Baldoni, M | 1 |
| Leonida, A | 1 |
| James, JL | 1 |
| Lukaszczyk, B | 1 |
| Cardinale, F | 1 |
| Yeh, AM | 1 |
| Yeh, CK | 1 |
| Harris, SE | 1 |
| Mohan, S | 1 |
| Horn, D | 1 |
| Fajardo, R | 1 |
| Chun, YH | 1 |
| Jorgensen, J | 1 |
| Macdougall, M | 1 |
| Abboud-Werner, S | 1 |
| Dijkema, T | 1 |
| Raaijmakers, CP | 1 |
| Braam, PM | 1 |
| Roesink, JM | 3 |
| Monninkhof, EM | 1 |
| Terhaard, CH | 1 |
| Matsuki-Fukushima, M | 1 |
| Okabayashi, K | 1 |
| Warde, P | 2 |
| O'Sullivan, B | 2 |
| Aslanidis, J | 1 |
| Kroll, B | 1 |
| Lockwood, G | 2 |
| Waldron, J | 2 |
| Payne, D | 1 |
| Bayley, A | 1 |
| Kim, J | 1 |
| Liu, FF | 1 |
| Maxymiw, W | 1 |
| Sprague, S | 1 |
| Cummings, BJ | 1 |
| Haddad, P | 1 |
| Karimi, M | 1 |
| Frydrych, AM | 1 |
| Davies, GR | 1 |
| Slack-Smith, LM | 1 |
| Heywood, J | 1 |
| Hawthorne, M | 1 |
| Sullivan, K | 1 |
| Brennan, MT | 2 |
| Shariff, G | 1 |
| Lockhart, PB | 2 |
| Fox, PC | 8 |
| Nagler, RM | 3 |
| Nagler, A | 3 |
| Nieuw Amerongen, AV | 1 |
| Veerman, EC | 1 |
| Fisher, J | 1 |
| Scott, C | 1 |
| Scarantino, CW | 1 |
| Leveque, FG | 3 |
| White, RL | 1 |
| Rotman, M | 1 |
| Hodson, DI | 2 |
| Meredith, RF | 1 |
| Foote, R | 2 |
| Bachman, DG | 1 |
| Lee, N | 2 |
| Vissink, A | 4 |
| Burlage, FR | 3 |
| Spijkervet, FK | 1 |
| Jansma, J | 1 |
| Coppes, RP | 3 |
| Omori, Y | 1 |
| Kojima, M | 1 |
| Shibata, N | 1 |
| Taylor, SE | 4 |
| Ben Slama, L | 1 |
| Djemil, M | 1 |
| Gorsky, M | 1 |
| Epstein, JB | 2 |
| Parry, J | 1 |
| Epstein, MS | 1 |
| Le, ND | 1 |
| Silverman, S | 1 |
| Bruce, SD | 1 |
| Solans, R | 1 |
| Bosch, JA | 1 |
| Selva, A | 1 |
| Simeón, CP | 1 |
| Fonollosa, V | 1 |
| Vilardell, M | 1 |
| Hendrickson, RG | 1 |
| Morocco, AP | 1 |
| Greenberg, MI | 1 |
| Torstenson, R | 1 |
| Gornitsky, M | 1 |
| Shenouda, G | 1 |
| Katz, H | 1 |
| Velly, AM | 1 |
| Kopittke, L | 1 |
| Gomez, R | 1 |
| Barros, HM | 1 |
| Chambers, MS | 1 |
| Keene, HJ | 1 |
| Toth, BB | 1 |
| Lemon, JC | 1 |
| Gallagher, SC | 6 |
| Martin, CG | 1 |
| Martin, JW | 1 |
| Shetty, K | 1 |
| Atkinson, JC | 4 |
| Grisius, M | 1 |
| Massey, W | 1 |
| Cummings, B | 1 |
| Masters, KJ | 1 |
| Sakaguchi, M | 1 |
| Goto, K | 1 |
| Ichiki, H | 1 |
| Hattori, N | 1 |
| Iizuka, A | 1 |
| Yamamoto, M | 1 |
| Takeda, S | 1 |
| Ishige, A | 1 |
| Aburada, M | 1 |
| Yasuda, M | 1 |
| Yamamoto, T | 1 |
| Sung, JM | 1 |
| Kuo, SC | 1 |
| Guo, HR | 1 |
| Chuang, SF | 1 |
| Lee, SY | 1 |
| Huang, JJ | 1 |
| Koukourakis, MI | 1 |
| Danielidis, V | 1 |
| Lewis, DM | 1 |
| Al-Hashimi, I | 3 |
| Kahn, ST | 1 |
| Johnstone, PA | 2 |
| de Castro, G | 1 |
| Federico, MH | 1 |
| Helcer, M | 2 |
| Livni, D | 2 |
| Markitziu, A | 3 |
| Scarantino, C | 1 |
| LeVeque, F | 2 |
| Swann, RS | 1 |
| White, R | 1 |
| Schulsinger, A | 1 |
| Meredith, R | 1 |
| Brachman, D | 1 |
| Koshihara, N | 1 |
| Tanaka Isomura, E | 1 |
| Yoshitomi, K | 1 |
| Hamaguchi, M | 1 |
| Yamamoto, YE | 1 |
| Kogo, M | 1 |
| Wu, CH | 1 |
| Hsieh, SC | 1 |
| Lee, KL | 1 |
| Li, KJ | 1 |
| Lu, MC | 1 |
| Yu, CL | 1 |
| Gause, A | 1 |
| Robinson, SD | 1 |
| Taweechaisupapong, S | 1 |
| Pesee, M | 1 |
| Aromdee, C | 2 |
| Laopaiboon, M | 1 |
| Khunkitti, W | 1 |
| Agha-Hosseini, F | 1 |
| Mirzaii-Dizgah, I | 1 |
| Ghavamzadeh, L | 1 |
| Ghavamzadeh, A | 1 |
| Tohidast-Acrad, Z | 1 |
| Davidovich, E | 1 |
| Peretz, B | 1 |
| Ngeow, WC | 1 |
| Chai, WL | 1 |
| Rahman, RA | 1 |
| Ramli, R | 1 |
| von Bültzingslöwen, I | 1 |
| Sollecito, TP | 1 |
| Daniels, T | 1 |
| Jonsson, R | 1 |
| Wray, D | 1 |
| Carrozzo, M | 1 |
| Gandera, B | 1 |
| Fujibayashi, T | 1 |
| Navazesh, M | 1 |
| Rhodus, NL | 4 |
| Schiødt, M | 2 |
| Shiboski, CH | 1 |
| Hodgson, TA | 1 |
| Ship, JA | 1 |
| Kampinga, HH | 2 |
| Terhaard, C | 1 |
| Langendijk, JA | 2 |
| van Luijk, P | 1 |
| Stokman, MA | 1 |
| Faber, H | 1 |
| Wick, JY | 1 |
| Sobocińska, J | 1 |
| Kozlowski, S | 1 |
| Wiseman, LR | 1 |
| Faulds, D | 1 |
| Singhal, S | 2 |
| Mehta, J | 2 |
| Rattenbury, H | 2 |
| Treleaven, J | 2 |
| Powles, R | 2 |
| Rieke, JW | 2 |
| Hafermann, MD | 1 |
| Johnson, JT | 2 |
| Iwamoto, R | 1 |
| Steiger, BW | 2 |
| Muscoplat, C | 1 |
| Singer, J | 1 |
| Ferguson, MM | 3 |
| O'Connell, AC | 2 |
| Pearson, SK | 1 |
| Bowen, WH | 1 |
| Joensuu, H | 2 |
| Ferretti, GA | 1 |
| Nethery, WJ | 1 |
| Valdez, IH | 3 |
| Ng, D | 1 |
| Muscoplat, CC | 2 |
| Boström, P | 1 |
| Makkonen, T | 1 |
| Wolff, A | 2 |
| Macynski, AA | 2 |
| Montgomery, M | 1 |
| Potter, D | 1 |
| Zimmer, MB | 1 |
| Salah, RS | 1 |
| Cameron, OG | 1 |
| Yamamoto, H | 1 |
| Sims, NE | 1 |
| Macauley, SP | 1 |
| Nguyen, KH | 1 |
| Nakagawa, Y | 1 |
| Humphreys-Beher, MG | 1 |
| Hamlar, DD | 1 |
| Schuller, DE | 2 |
| Gahbauer, RA | 1 |
| Buerki, RA | 1 |
| Staubus, AE | 1 |
| Hall, J | 1 |
| Altman, JS | 1 |
| Elzinga, DJ | 1 |
| Martin, MR | 1 |
| Jacobs, CD | 1 |
| van der Pas, M | 1 |
| Fawcett, JP | 1 |
| Ledger, R | 1 |
| Zimmerman, RP | 1 |
| Mark, RJ | 1 |
| Tran, LM | 1 |
| Juillard, GF | 1 |
| Martínez-Gomis, J | 1 |
| Planas, ME | 1 |
| Planelles, X | 1 |
| Bartrons, R | 1 |
| Sánchez, S | 1 |
| Oda, M | 1 |
| Sato, M | 1 |
| Yagi, N | 1 |
| Ohno, K | 1 |
| Miyazaki, S | 1 |
| Watanabe, S | 1 |
| Takada, M | 1 |
| Takaya, M | 1 |
| Ichikawa, Y | 1 |
| Yamada, C | 1 |
| Hoshina, Y | 1 |
| Horiki, T | 1 |
| Uchiyama, M | 1 |
| Garg, AK | 1 |
| Malo, M | 1 |
| Daniels, C | 1 |
| Pugh, R | 1 |
| Sharma, K | 1 |
| Papas, AS | 1 |
| Fernandez, MM | 1 |
| Castano, RA | 1 |
| Trivedi, M | 1 |
| Shrotriya, RC | 2 |
| Nelson, JD | 1 |
| Friedlaender, M | 1 |
| Yeatts, RP | 1 |
| Yee, R | 1 |
| McDermott, M | 1 |
| Orlin, S | 1 |
| Niedermeier, W | 1 |
| Matthaeus, C | 1 |
| Meyer, C | 1 |
| Staar, S | 1 |
| Müller, RP | 1 |
| Schulze, HJ | 1 |
| Deutsch, M | 1 |
| Tishler, M | 1 |
| Cooper, RA | 1 |
| Cowan, RA | 1 |
| Owens, SE | 1 |
| Jeans, SP | 1 |
| Roberts, JK | 1 |
| Hillel, PG | 1 |
| Slevin, NJ | 1 |
| Allan, E | 1 |
| Gupta, NK | 1 |
| Collins, CD | 1 |
| Liljemark, W | 1 |
| Bloomquist, C | 1 |
| Bereuter, J | 1 |
| Miller, EG | 1 |
| Stone, P | 1 |
| A'Hern, R | 1 |
| Blom, M | 1 |
| Kopp, S | 1 |
| Lundeberg, T | 1 |
| Nusair, S | 1 |
| Rubinow, A | 1 |
| Nagler, R | 1 |
| Lajtman, Z | 1 |
| Krajina, Z | 1 |
| Krpan, D | 1 |
| Vincelj, J | 1 |
| Borcić, V | 1 |
| Popović-Kovacić, J | 1 |
| Horiot, JC | 1 |
| Lipinski, F | 1 |
| Schraub, S | 1 |
| Maulard-Durdux, C | 1 |
| Bensadoun, RJ | 1 |
| Ardiet, JM | 1 |
| Bolla, M | 1 |
| Coscas, Y | 1 |
| Baillet, F | 1 |
| Coche-Dequéant, B | 1 |
| Urbajtel, M | 1 |
| Montbarbon, X | 1 |
| Bourdin, S | 1 |
| Wibault, M | 1 |
| Alfonsi, M | 1 |
| Calais, G | 1 |
| Desprez, P | 1 |
| Pene, F | 1 |
| Lapeyre, M | 1 |
| Vinke, J | 1 |
| Maral, J | 1 |
| Canapp, SO | 1 |
| Cohn, LA | 1 |
| Maggs, DJ | 1 |
| Miller, MA | 1 |
| Kerl, ME | 1 |
| O'Brien, DP | 1 |
| Mercadante, S | 1 |
| Calderone, L | 1 |
| Villari, P | 1 |
| Serretta, R | 1 |
| Sapio, M | 1 |
| Casuccio, A | 1 |
| Fulfaro, F | 1 |
| Vidal, E | 1 |
| Liozon, E | 1 |
| Soria, P | 1 |
| Sangthawan, D | 1 |
| Watthanaarpornchai, S | 1 |
| Phungrassami, T | 1 |
| Peng, YP | 1 |
| May, BC | 1 |
| Inouye, WS | 1 |
| Niemtzow, RC | 1 |
| Mateos, JJ | 1 |
| Setoain, X | 1 |
| Ferre, J | 1 |
| Rovirosa, A | 1 |
| Navalpotro, B | 1 |
| Martin, F | 1 |
| Ortega, M | 1 |
| Lomeña, F | 1 |
| Fuster, D | 1 |
| Pavia, J | 1 |
| Pons, F | 1 |
| Komatsu, Y | 1 |
| Misawa, K | 1 |
| Hara, K | 1 |
| Akahane, M | 1 |
| Leek, H | 1 |
| Albertsson, M | 1 |
| Baum, BJ | 3 |
| Muzyka, BC | 1 |
| Rosas, J | 1 |
| Ramos-Casals, M | 1 |
| Ena, J | 1 |
| García-Carrasco, M | 1 |
| Verdu, J | 1 |
| Cervera, R | 1 |
| Font, J | 1 |
| Caballero, O | 1 |
| Ingelmo, M | 1 |
| Pascual, E | 1 |
| Gelinsky, P | 1 |
| Bassuk, E | 1 |
| Schoonover, S | 1 |
| Weaver, ML | 2 |
| Tanzer, JM | 2 |
| Kramer, PA | 2 |
| Niedermeier, WH | 1 |
| Krämer, R | 1 |
| Kusler, DL | 1 |
| Rambur, BA | 1 |
| Zelles, T | 1 |
| Blazsek, J | 1 |
| Kelemen, E | 1 |
| Schuh, MJ | 1 |
| Hayes, P | 1 |
| Highton, J | 1 |
| Jones, DS | 1 |
| MacFadyen, EE | 1 |
| Palmer, DG | 1 |
| Kung, DS | 1 |
| Jackson, W | 1 |
| Delapenha, RA | 1 |
| Shiroky, J | 1 |
| Butt, GM | 1 |
| Greenspan, D | 2 |
| Stevens, P | 1 |
| Clausen, KP | 1 |
| Olsen, J | 1 |
| Gahbauer, R | 1 |
| Martin, M | 1 |
| Arrago, JP | 1 |
| Rain, JD | 1 |
| Brocheriou, C | 1 |
| Rocher, F | 1 |
| Schubert, MM | 1 |
| van der Ven, PF | 1 |
| Mandel, ID | 1 |
| Daniels, TE | 1 |
| Szabó, G | 1 |
| Panders, AK | 1 |
| s'-Gravenmade, EJ | 1 |
| Vermey, A | 1 |
| Fourestier, J | 1 |
| Gacon, J | 1 |
| Brisou, B | 1 |
| Le Stir, A | 1 |
| Morcelet, JL | 1 |
| Lingjaerde, O | 1 |
| Rand, MJ | 1 |
| Rush, M | 1 |
| Wilson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Xerostomia in Patients With a Life-limiting Condition or Frailty: a Double-blind Placebo-controlled Randomized Clinical Trial[NCT05506137] | Phase 3 | 120 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | ||
| Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome[NCT04470479] | Phase 3 | 32 participants (Actual) | Interventional | 2005-03-01 | Completed | ||
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| Analysis of the Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome[NCT03711214] | 80 participants (Anticipated) | Interventional | 2018-12-01 | Active, not recruiting | |||
| Effect of Pilocarpine in Patients With Xerostomia[NCT02982577] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Finger-prick Autologous Blood (FAB) for Use in Dry Mouth[NCT03530735] | 20 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | |||
| A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia[NCT00656513] | Phase 2/Phase 3 | 196 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer[NCT01066741] | Phase 3 | 78 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to insufficient recruitment, the planed sample size appears not achievable) | ||
| A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated With Curative Radiation Therapy in Head and Neck Cancer Patients[NCT00003139] | Phase 3 | 249 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University[NCT03883152] | 131 participants (Actual) | Observational | 2017-06-27 | Completed | |||
| Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva[NCT00438048] | Phase 4 | 76 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome[NCT00001598] | Phase 2 | 28 participants | Interventional | 1997-05-31 | Completed | ||
| An Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray on the Relief of Dry Mouth Symptoms[NCT04186806] | 40 participants (Actual) | Interventional | 2019-11-02 | Completed | |||
| Multicenter, Controlled Parallel Groups Trial to Evaluate the Efficacy, Safety and Acceptability of OGT Oromucosal Spray Versus a Saliva Substitute in the Treatment of Xerostomia in Geriatrics[NCT00350350] | 74 participants (Actual) | Observational | 2003-10-31 | Completed | |||
| Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia[NCT00332618] | 74 participants | Observational | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This secondary objective was to evaluate the effect of ALTENS treatment on overall radiation-induced xerostomia burden by looking at treatment response. Treatment response was determined by a reduction of at least 20% from baseline to 6 months in the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4. Higher scores indicate increased xerostomia burden. This scale has high reproducibility and sensitivity. For the first and second stage analyses, 4 and 10 patients, respectively, must respond to treatment in order to proceed to the phase III component. (NCT00656513)
Timeframe: Pre-treatment and 6 months from registration
| Intervention | percentage of participants (Number) |
|---|---|
| ALTENS: Phase II | 85.7 |
Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden. (NCT00656513)
Timeframe: Baseline (randomization) and 9 months
| Intervention | units on a scale (Median) |
|---|---|
| Pilocarpine: Phase III | -0.27 |
| ALTENS: Phase III | -0.53 |
The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement. (NCT00656513)
Timeframe: Baseline and 9 months from randomization.
| Intervention | units on a scale (Median) |
|---|---|
| Pilocarpine: Phase III | -3.64 |
| ALTENS: Phase III | -7.27 |
Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden. (NCT00656513)
Timeframe: Baseline, 4, 6, and 15 months from randomization
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| 4 months | 6 months | 15 months | |
| ALTENS: Phase III | -0.47 | -0.4 | -0.6 |
| Pilocarpine: Phase III | -0.27 | -0.33 | -0.47 |
Stimulated (citric acid primed) whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. Stimulation is elicited by asking patients to rinse 5 ml of 2% citric acid solution in the mouth for 15 seconds and then completely expectorating the citric acid. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected. (NCT00656513)
Timeframe: Baseline, 4, 6, 9 and 15 months from randomization
| Intervention | ml/min (Median) | |||
|---|---|---|---|---|
| 4 months | 6 months | 9 months | 15 months | |
| ALTENS: Phase III | 0.2 | 0.40 | 0.60 | 0.20 |
| Pilocarpine: Phase III | 0.03 | 0.2 | 0.99 | 0.3 |
Symptom burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning. The domain score is the average of all responses on a given domain and can range from 0 to 4, with higher scores indicating increased symptom burden. Change in symptom burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the symptom burden. (NCT00656513)
Timeframe: Baseline, 4, 6, 9 and 15 months from randomization
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4-month Physical Functioning | 4-month Pain/Discomfort | 4-month Personal/Psychological Functioning | 4-month Social Functioning | 6-month Physical Functioning | 6-month Pain/Discomfort | 6-month Personal/Psychological Functioning | 6-month Social Functioning | 9-month Physical Functioning | 9-month Pain/Discomfort | 9-month Personal/Psychological Functioning | 9-month Social Functioning | 15-month Physical Functioning | 15-month Pain/Discomfort | 15-month Personal/Psychological Functioning | 15-month Social Functioning | |
| ALTENS: Phase III | -0.5 | -0.375 | -0.5 | -0.33 | -0.5 | -0.5 | -0.5 | -0.33 | -0.5 | -0.5 | -0.75 | -0.33 | -0.75 | -0.5 | -0.75 | -0.33 |
| Pilocarpine: Phase III | -0.5 | -0.25 | -0.25 | 0 | -0.5 | -0.25 | -0.25 | -0.33 | -0.5 | -0.25 | -0.5 | -0.66 | -0.5 | -0.5 | -0.5 | 0 |
Basal whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected. (NCT00656513)
Timeframe: Pre-treatment to 4, 6, 9 and 15 months from randomization
| Intervention | ml/min (Median) | |||
|---|---|---|---|---|
| 4 months | 6 months | 9 months | 15 months | |
| ALTENS: Phase III | 0 | 0.02 | 0.04 | 0.192 |
| Pilocarpine: Phase III | 0 | 0 | 0.056 | 0.13 |
Patients completing at least 19 out of 24 ALTENS therapy sessions were categorized as compliant. Fleming's two-stage was used, assuming a successful target compliance rate of 80%, statistical power of 0.87, and a type I error rate of 0.13. If fewer than 9 of the first 13 patients were compliant, then treatment delivery will be deemed not feasible. If there were between 9-12 compliant patients, the second stage analysis would be required to determine feasibility of treatment delivery. If all 13 patients are compliant, treatment delivery will immediately be deemed feasible. The second stage analysis required at least 31 compliant out of 39 overall patients for the treatment delivery to be deemed feasible. (NCT00656513)
Timeframe: Randomization to 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| First Stage | Second Stage (Overall) | |
| ALTENS: Phase II | 12 | 44 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 120 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.86 |
| Biotene Moisturizing Mouth Spray | 5.41 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 30 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.51 |
| Biotene Moisturizing Mouth Spray | 4.75 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 60 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.58 |
| Biotene Moisturizing Mouth Spray | 5.04 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 240 minutes post dose
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 5.14 |
| Biotene Moisturizing Mouth Spray | 5.68 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 5 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.54 |
| Biotene Moisturizing Mouth Spray | 4.62 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 15 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.394 |
| Biotene Moisturizing Mouth Spray | -2.036 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 30 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.420 |
| Biotene Moisturizing Mouth Spray | -1.900 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 5 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.203 |
| Biotene Moisturizing Mouth Spray | -1.871 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 120 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.364 |
| Biotene Moisturizing Mouth Spray | -1.657 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 240 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M Dry Mouth Moisturizing Spray | -2.322 |
| Biotene Moisturizing Mouth Spray | -1.665 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 60 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.455 |
| Biotene Moisturizing Mouth Spray | -1.833 |
Primary endpoint will be paired-difference in Visual Analog Scale (VAS) between experimental and active control product. On the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms. (NCT04186806)
Timeframe: 15 minutes post dose
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.51 |
| Biotene Moisturizing Mouth Spray | 4.6 |
39 reviews available for pilocarpine and Xerostomia
| Article | Year |
|---|---|
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
Topics: Amifostine; Drugs, Chinese Herbal; Female; Fibroblast Growth Factor 7; Humans; Male; Pilocarpine; Qu | 2017 |
Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
Topics: Drug Delivery Systems; Head and Neck Neoplasms; Humans; Mouth Mucosa; Muscarinic Agonists; Pilocarpi | 2018 |
Salivary hypofunction: An update on therapeutic strategies.
Topics: Acupuncture Therapy; Bethanechol; Chewing Gum; Humans; Hyperbaric Oxygenation; Muscarinic Agonists; | 2018 |
Interventions for dry mouth and hyposalivation in Sjögren's syndrome: A systematic review and meta-analysis.
Topics: Humans; Muscarinic Agonists; Pilocarpine; Quality of Life; Randomized Controlled Trials as Topic; Sa | 2019 |
[Prognosis and treatment of dry mouth. Systematic review].
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Dental Caries; Disease Susceptibility; Double-Bli | 2014 |
Systematic literature review: xerostomia in advanced cancer patients.
Topics: Acupuncture Therapy; Adult; Chewing Gum; Disease Progression; Humans; Neoplasms; Pilocarpine; Prospe | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.
Topics: Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Treatment Outcome; Xerostomia | 2016 |
Is Pilocarpine Effective in Preventing Radiation-Induced Xerostomia? A Systematic Review and Meta-analysis.
Topics: Cholinergic Agonists; Head and Neck Neoplasms; Humans; Pilocarpine; Prospective Studies; Quality of | 2016 |
Systemic pilocarpine for treatment of xerostomia.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation I | 2008 |
Managing the patient presenting with xerostomia: a review.
Topics: Acupuncture Therapy; Ascorbic Acid; Chewing Gum; Humans; Malates; Medical History Taking; Muscarinic | 2010 |
Scleroderma and CREST syndrome: a case report in dentistry.
Topics: Aged; Combined Modality Therapy; CREST Syndrome; Deglutition Disorders; Dental Caries; Dentures; Dis | 2011 |
Pilocarpine for radiation-induced xerostomia in head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Randomized Co | 2000 |
Treatment of xerostomia: a systematic review of therapeutic trials.
Topics: Acupuncture Therapy; Bias; Humans; Muscarinic Agonists; Pilocarpine; Radiotherapy; Randomized Contro | 2002 |
Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
Topics: Acupuncture Therapy; Antineoplastic Agents; Chewing Gum; Diet; Flavoring Agents; Humans; Muscarinic | 2003 |
Prevention and treatment of the consequences of head and neck radiotherapy.
Topics: Anti-Bacterial Agents; Cranial Irradiation; Dental Caries; Dysgeusia; Head and Neck Neoplasms; Human | 2003 |
Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia.
Topics: Antifungal Agents; Cost-Benefit Analysis; Fluorides; Head and Neck Neoplasms; Humans; Muscarinic Ago | 2003 |
Radiation-induced xerostomia: how dry is your patient?
Topics: Acupuncture Therapy; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Nurse's Role; Nursing Ass | 2004 |
Salivary hypofunction and xerostomia: diagnosis and treatment.
Topics: Aged; Aged, 80 and over; Cariostatic Agents; Fluorides; Humans; Pilocarpine; Polypharmacy; Quinuclid | 2005 |
Preventing radiation induced xerostomia.
Topics: Head and Neck Neoplasms; Humans; Incidence; Muscarinic Agonists; Pilocarpine; Quality of Life; Radia | 2005 |
Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Humans; Muscarinic Agonists; Pilocarpine; Quinucli | 2005 |
Management of xerostomia related to radiotherapy for head and neck cancer.
Topics: Acupuncture Therapy; Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Muscarin | 2005 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S | 2006 |
[Pharmacological and clinical profile of pilocarpine hydrochloride (SALAGEN) Tab. 5 mg)].
Topics: Animals; Humans; Muscarinic Agonists; Pilocarpine; Radiotherapy; Receptors, Muscarinic; Saliva; Xero | 2006 |
Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia.
Topics: Chewing Gum; Head and Neck Neoplasms; Humans; Mouthwashes; Parasympatholytics; Pilocarpine; Radiatio | 2006 |
Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Diabetes Complicat | 2007 |
Management of salivary hypofunction during and after radiotherapy.
Topics: Amifostine; Dental Caries; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation-P | 2007 |
Xerostomia: causes and treatment.
Topics: Autoimmune Diseases; Bone Marrow Transplantation; Drug-Related Side Effects and Adverse Reactions; H | 2007 |
Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.
Topics: Controlled Clinical Trials as Topic; Humans; Pilocarpine; Radiotherapy; Randomized Controlled Trials | 1995 |
Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction.
Topics: Anethole Trithione; Bethanechol; Bethanechol Compounds; Humans; Parasympathomimetics; Pilocarpine; P | 1993 |
Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy.
Topics: Cariostatic Agents; Chronic Disease; Dental Caries; Fluorides; Gels; Head and Neck Neoplasms; Humans | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Pilocarpine, an old drug; a new formulation.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Humans; Parasympathomimetics; Pilocarpine; Salivary | 1996 |
[Pilocarpine--new use for an old drug].
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Radiotherapy; Xe | 1998 |
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease; | 1999 |
The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation I | 1999 |
[New therapeutic strategies for xerostomia in chronic graft versus host disease patients].
Topics: Animals; Chronic Disease; Cytokines; Graft vs Host Disease; Humans; Muscarinic Agonists; Pilocarpine | 2000 |
[Dry mouth].
Topics: Candidiasis, Oral; Dental Caries; Diagnosis, Differential; Humans; Medical History Taking; Muscarini | 2001 |
Natural history and prevention of radiation injury.
Topics: Animals; Disease Models, Animal; Disease Progression; Free Radical Scavengers; Humans; Muscarinic Ag | 2000 |
57 trials available for pilocarpine and Xerostomia
| Article | Year |
|---|---|
Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial.
Topics: Humans; Mouthwashes; Pilocarpine; Saliva; Xerostomia | 2022 |
Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial.
Topics: Humans; Mouthwashes; Pilocarpine; Saliva; Xerostomia | 2022 |
Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial.
Topics: Humans; Mouthwashes; Pilocarpine; Saliva; Xerostomia | 2022 |
Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial.
Topics: Humans; Mouthwashes; Pilocarpine; Saliva; Xerostomia | 2022 |
Dry mouth in patients with a life-limiting condition or frailty: a study protocol for two intervention studies and a nested qualitative sub-study (the Dry mOuth Project, DROP).
Topics: Frailty; Humans; Inpatients; Non-Randomized Controlled Trials as Topic; Pilocarpine; Quality of Life | 2023 |
Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarini | 2018 |
Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder.
Topics: Aged; Cholinergic Antagonists; Double-Blind Method; Drug Combinations; Female; Humans; Incidence; Ma | 2019 |
Effect of 0.1% pilocarpine mouthwash on xerostomia: double-blind, randomised controlled trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Mouthwashes; Muscarinic Agonists; Pil | 2014 |
Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Pilocarpine; Radiation-Protective Agents; Rad | 2014 |
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study.
Topics: Acupuncture Therapy; Adult; Aged; Drug Administration Schedule; Female; Humans; Intention to Treat A | 2015 |
Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study.
Topics: Administration, Buccal; Cell Transformation, Neoplastic; Cholinergic Agents; Cross-Over Studies; Fea | 2015 |
Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial.
Topics: Administration, Oral; Adult; Aged; Cholinergic Agents; Female; Head and Neck Neoplasms; Health Statu | 2008 |
Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia.
Topics: Administration, Oral; Aged; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck N | 2009 |
Phase II Randomized Trial of Acupuncture-Like Transcutaneous Electrical Nerve Stimulation to Prevent Radiation-Induced Xerostomia in Head and Neck Cancer Patients.
Topics: Acupuncture Therapy; Head and Neck Neoplasms; Humans; Pilocarpine; Transcutaneous Electric Nerve Sti | 2010 |
Tramadol-induced oral dryness and pilocarpine treatment: effects on total protein and IgA.
Topics: Analysis of Variance; Humans; Immunoglobulin A; Muscarinic Agonists; Narcotics; Pilocarpine; Saliva; | 2011 |
Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Multivariate Analysis; Muscarinic Agonists; P | 2012 |
Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia.
Topics: Acupuncture; Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Male; Middle A | 2012 |
Xerostomia: a day and night difference.
Topics: Adult; Aged; Aged, 80 and over; Circadian Rhythm; Dose-Response Relationship, Radiation; Double-Blin | 2012 |
A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer.
Topics: Administration, Oral; Adult; Aged; Cholinergic Agents; Double-Blind Method; Female; Head and Neck Ne | 2002 |
A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedule; He | 2002 |
An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia.
Topics: Aerosols; Aged; Candida; Colony Count, Microbial; Double-Blind Method; Follow-Up Studies; Humans; Mi | 2002 |
Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
Topics: Female; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Male; Middle Aged; Muscarinic | 2003 |
The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Attitude to Health; Bethanechol; Cross-Over Studies; Female; Head an | 2004 |
Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Analysis of Variance; Double-Blind Method; Female; | 2004 |
Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer.
Topics: Analysis of Variance; Cranial Irradiation; Double-Blind Method; Female; Head and Neck Neoplasms; Hum | 2004 |
Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study.
Topics: Analgesics, Opioid; Colony Count, Microbial; Female; Follow-Up Studies; Humans; Longitudinal Studies | 2005 |
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia.
Topics: Carcinoma, Squamous Cell; Confidence Intervals; Female; Head and Neck Neoplasms; Health Status; Huma | 2005 |
Decreased salivary flow rate as a dipsogenic factor in hemodialysis patients: evidence from an observational study and a pilocarpine clinical trial.
Topics: Body Weight; Cross-Over Studies; Humans; Kinetics; Muscarinic Agonists; Pilocarpine; Pilot Projects; | 2005 |
Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
Topics: Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Muscarinic Agonists; Pilocarpine; Qualit | 2006 |
Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Pilocarpine; R | 2006 |
Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer.
Topics: Adult; Cranial Irradiation; Cross-Over Studies; Double-Blind Method; Female; Head and Neck Neoplasms | 2006 |
Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Double-Blind Method; Female; Head and Neck Neopla | 2008 |
Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease.
Topics: Administration, Oral; Graft vs Host Disease; Humans; Mouth Mucosa; Pilocarpine; Saliva; Xerostomia | 1995 |
Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; He | 1995 |
A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pilocarpine; Prospective Studies; Radiot | 1994 |
Scientists find remedy for patients' suffering from post-irradiation xerostomia.
Topics: Cranial Irradiation; Humans; Pilocarpine; Xerostomia | 1994 |
Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer.
Topics: Administration, Oral; Aged; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Midd | 1993 |
Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction.
Topics: Adult; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilocarpine; | 1993 |
A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.
Topics: Administration, Oral; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Age | 1993 |
Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Head and Neck Neoplasms; | 1996 |
A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia.
Topics: Administration, Oral; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 1996 |
Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies.
Topics: Bone Marrow Transplantation; Chronic Disease; Graft vs Host Disease; Hematologic Neoplasms; Humans; | 1997 |
Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia.
Topics: Cohort Studies; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Pilocarpine; Pilot Pr | 1997 |
[Treatment with pilocarpine hydrochloride for sicca symptoms in Sjögren's syndrome].
Topics: Administration, Oral; Adult; Aged; Female; Humans; Middle Aged; Parasympathomimetics; Pilocarpine; S | 1997 |
A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Home Care Services; Hospitalization; Hum | 1998 |
Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Double-Blind Method; Dry Eye Syndromes; Electr | 1998 |
Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group.
Topics: Administration, Oral; Double-Blind Method; Humans; Keratoconjunctivitis Sicca; Miotics; Pilocarpine; | 1998 |
Radiation-induced hyposalivation and its treatment with oral pilocarpine.
Topics: Carcinoma, Squamous Cell; Cranial Irradiation; Female; Head and Neck Neoplasms; Humans; Male; Middle | 1998 |
Pilocarpine in the prevention of postirradiation xerostomia.
Topics: Double-Blind Method; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiotherapy | 2000 |
Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Male; | 2000 |
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.
Topics: Aged; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Muscarinic Ag | 2001 |
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies.
Topics: Acupuncture Therapy; Drug Resistance; Head and Neck Neoplasms; Humans; Miotics; Pilocarpine; Radiati | 2001 |
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Mi | 2001 |
Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anethole Trithione; Cholinergic Agents; Female; Humans; | 2002 |
Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Parotid Gland; Patient Satisfaction; Pilocarpine; Sa | 1991 |
Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia).
Topics: Adolescent; Adult; Aged; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Male; Midd | 1991 |
Treatment of radiation side effects with oral pilocarpine.
Topics: Administration, Oral; Double-Blind Method; Head and Neck Neoplasms; Humans; Pilocarpine; Pilot Proje | 1989 |
Synergistic effect of sialagogues in management of xerostomia after radiation therapy.
Topics: Adult; Aged; Anethole Trithione; Anisoles; Clinical Trials as Topic; Drug Synergism; Drug Therapy, C | 1987 |
Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Middle Aged; Pilocarpine; Place | 1986 |
Effectiveness of pilocarpine in postradiation xerostomia.
Topics: Carcinoma; Head and Neck Neoplasms; Humans; Parotid Gland; Pilocarpine; Radiotherapy; Salivation; Xe | 1987 |
99 other studies available for pilocarpine and Xerostomia
| Article | Year |
|---|---|
Topical Xerostomia Treatment with Hyaluronate Sheets Containing Pilocarpine.
Topics: Head and Neck Neoplasms; Humans; Pilocarpine; Salivary Glands; Salivation; Xerostomia | 2022 |
Protective Effect of Electroacupuncture on Chemotherapy-Induced Salivary Gland Hypofunction in a Mouse Model.
Topics: Animals; Antineoplastic Agents; Electroacupuncture; Fluorouracil; Immunoglobulin A, Secretory; Mice; | 2023 |
Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Agonists; Pilocarpine; Quinu | 2019 |
Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.
Topics: Antineoplastic Agents; Female; Humans; Nivolumab; Pilocarpine; Prednisolone; Salivary Glands; Sjogre | 2020 |
Local Oral Pilocarpine Drops for Relieving Xerostomia (Dry Mouth) in the Elderly: A Pilot Study.
Topics: Aged; Humans; Pilocarpine; Pilot Projects; Xerostomia | 2021 |
Long-term Use of the Sialogogue Medications Pilocarpine and Cevimeline Can Reduce Xerostomia Symptoms and Increase Salivary Flow in Head and Neck Cancer Survivors After Radiotherapy.
Topics: Head and Neck Neoplasms; Humans; Pilocarpine; Quinuclidines; Survivors; Thiophenes; Xerostomia | 2017 |
Epithelial disruptions, but not immune cell invasion, induced secretory dysfunction following innate immune activation in a novel model of acute salivary gland injury.
Topics: Animals; Anoctamin-1; Antigens, Ly; Aquaporin 5; Basement Membrane; Down-Regulation; Female; Gene Ex | 2018 |
Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation.
Topics: Animals; Dose Fractionation, Radiation; Female; Humans; Male; Mice; Mice, Inbred C57BL; Pilocarpine; | 2018 |
A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride.
Topics: Chemoradiotherapy; Humans; Male; Middle Aged; Muscarinic Agonists; Nephritis, Interstitial; Pharynge | 2019 |
Buccal adhesive chitosan conjugate comprising pilocarpine for xerostomia.
Topics: Adhesives; Cell Line; Chitosan; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery S | 2019 |
Neuroleptic drugs.
Topics: Antipsychotic Agents; Humans; Muscarinic Agonists; Pilocarpine; Xerostomia | 2012 |
Preserving formerly impaired salivary gland function in radioiodine-treated thyroid papillary carcinoma.
Topics: Adult; Carcinoma; Carcinoma, Papillary; Endoscopy, Digestive System; Female; Humans; Iodine Radioiso | 2013 |
Functional salivary gland regeneration by transplantation of a bioengineered organ germ.
Topics: Animals; Citric Acid; Embryo, Mammalian; Embryonic Stem Cells; Epithelial Cells; Graft Survival; Mes | 2013 |
Changes of salivary functions in experimental periodontitis model rats.
Topics: Acinar Cells; Animals; Apoptosis; Blotting, Western; Calcium; Disease Models, Animal; Ligation; Male | 2014 |
Endangered Jaborandi.
Topics: Endangered Species; Glaucoma; Humans; Pilocarpine; Piper; Xerostomia | 2014 |
Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucocortic | 2016 |
Parasympathomimetic drugs for dry mouth due to radiotherapy.
Topics: Humans; Odds Ratio; Parasympathomimetics; Pilocarpine; Xerostomia | 2016 |
Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Carcinoma; Dose-Response Relationship, Drug; Drug Admin | 2009 |
Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B.
Topics: Aged; Anti-Dyskinesia Agents; Botulinum Toxins; Botulinum Toxins, Type A; Female; Humans; Muscarinic | 2008 |
Effect of Pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic | 2008 |
[Mouth dryness].
Topics: Aged; Antidepressive Agents, Tricyclic; Cholinergic Agents; Cholinergic Antagonists; Humans; Male; P | 2008 |
Symptomatic unilateral submandibular gland aplasia.
Topics: Adult; Cholinergic Agents; Female; Humans; Pilocarpine; Saliva, Artificial; Salivary Gland Diseases; | 2009 |
Salivation triggered by pilocarpine involves aquaporin-5 in normal rats but not in irradiated rats.
Topics: Animals; Aquaporin 5; Calcium; Male; Muscarinic Agonists; Muscarinic Antagonists; Parotid Gland; Pil | 2009 |
E2F1-deficient NOD/SCID mice are an experimental model for dry mouth.
Topics: Animals; Disease Models, Animal; Drinking Behavior; E2F1 Transcription Factor; Mice; Mice, Inbred NO | 2009 |
Cholinergic autoantibodies from primary Sjögren's syndrome modulate submandibular gland Na+/K+-ATPase activity via prostaglandin E2 and cyclic AMP.
Topics: Adult; Animals; Autoantibodies; Cells, Cultured; Cyclic AMP; Dinoprostone; Female; Humans; Immunoglo | 2010 |
Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
Topics: Administration, Oral; Adolescent; Child; Female; Humans; Male; Muscarinic Agonists; Pilocarpine; Pil | 2010 |
Hyperglycemia and xerostomia are key determinants of tooth decay in type 1 diabetic mice.
Topics: Amelogenin; Animals; Dental Caries; Dental Enamel Proteins; Diabetes Mellitus, Type 1; Female; Hyper | 2012 |
E2f1-deficient NOD/SCID mice have dry mouth due to a change of acinar/duct structure and the down-regulation of AQP5 in the salivary gland.
Topics: Acinar Cells; Animals; Aquaporin 5; Cell Membrane; Cytosol; Down-Regulation; Drinking; E2F1 Transcri | 2013 |
Drug used during radiotherapy helps reduce dry mouth problem.
Topics: Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Xerostomia | 2001 |
Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly.
Topics: Administration, Oral; Drug Costs; France; Humans; Muscarinic Agonists; Pilocarpine; Radiotherapy; Ra | 2002 |
Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease--a prolonged study.
Topics: Adolescent; Adult; Albumins; Cations; Chronic Disease; Epidermal Growth Factor; Female; Follow-Up St | 2003 |
Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Topics: Animals; Antipsychotic Agents; Body Temperature; Cardiovascular System; Central Nervous System; Chlo | 2003 |
[Pilocarpin].
Topics: Humans; Muscarinic Agonists; Pilocarpine; Salivary Glands; Xerostomia | 2003 |
[Usefulness of oral pilocarpin therapy in the treatment of xerostomia and xerophthalmia in patients with primary Sjögren's syndrome].
Topics: Administration, Oral; Adult; Aged; Female; Humans; Male; Middle Aged; Miotics; Pilocarpine; Sjogren' | 2004 |
Pilocarpine toxicity and the treatment of xerostomia.
Topics: Administration, Oral; Drug Overdose; Female; Humans; Middle Aged; Muscarinic Agonists; Pilocarpine; | 2004 |
Opposite effects of antidepressants on unstimulated and stimulated salivary flow.
Topics: Amylases; Animals; Antidepressive Agents; Calcium; Fluoxetine; Imipramine; Male; Moclobemide; Muscar | 2005 |
Dentistry. Implications and management of xerostomia in the HIV patient.
Topics: Antiretroviral Therapy, Highly Active; Cholinergic Agents; HIV Infections; HIV Protease Inhibitors; | 2005 |
Pilocarpine treatment of xerostomia induced by psychoactive medications.
Topics: Adult; Aged; Humans; Mental Disorders; Middle Aged; Muscarinic Agonists; Pilocarpine; Psychotropic D | 2005 |
Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats.
Topics: Animals; Drugs, Chinese Herbal; Male; Mandelic Acids; Muscle Contraction; Pilocarpine; Plant Extract | 2005 |
Xerostomia: a clinical approach.
Topics: Humans; Muscarinic Agonists; Pilocarpine; Saliva; Saliva, Artificial; Salivation; Xerostomia | 2005 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi | 2006 |
Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer.
Topics: Adult; Aged; Blood Pressure; Body Temperature; Chronic Disease; Dental Caries; Female; Heart Rate; H | 2006 |
Transplantation of vascularized submandibular gland in dogs.
Topics: Animals; Cholinergic Agents; Chorda Tympani Nerve; Dogs; Female; Immunosuppressive Agents; Jugular V | 2006 |
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome].
Topics: Bromhexine; Cyclosporine; Dry Eye Syndromes; Electric Stimulation Therapy; Expectorants; Humans; Mus | 2007 |
Pilocarpine treatment in a mixed cohort of xerostomic patients.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Body Temperature; Cohort Studies; Dizziness; Drug-Re | 2007 |
Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD).
Topics: Administration, Oral; Adult; Calcium; Double-Blind Method; Female; Graft vs Host Disease; Humans; Im | 2007 |
Prevention of oral and salivary gland impairment in irradiated adolescent patients with head and neck cancer: a suggested protocol.
Topics: Adolescent; Child; Clinical Protocols; Cranial Irradiation; Dental Caries; Head and Neck Neoplasms; | 2007 |
Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment.
Topics: Animals; Male; Muscarinic Antagonists; Parotid Gland; Pilocarpine; Radiation Injuries, Experimental; | 2008 |
Salivary flow and thrist.
Topics: Animals; Atropine; Dogs; Pilocarpine; Saliva; Salivation; Thirst; Xerostomia | 1967 |
Oral pilocarpine for xerostomia.
Topics: Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Pilocarpine; Radiation Injuries; Radiothe | 1994 |
Pilocarpine alters caries development in partially-desalivated rats.
Topics: Analysis of Variance; Animals; Cariostatic Agents; Dental Caries; Female; Parotid Gland; Pilocarpine | 1994 |
Treatment for post-irradiation xerostomia.
Topics: Contraindications; Humans; Pilocarpine; Radiotherapy; Salivary Glands; Xerostomia | 1994 |
Treatment for post-irradiation xerostomia.
Topics: Carbachol; Head and Neck Neoplasms; Humans; Pilocarpine; Radiotherapy; Xerostomia | 1994 |
Pilocarpine and carbacholine in treatment of radiation-induced xerostomia.
Topics: Adult; Aged; Carbachol; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Mi | 1993 |
Pilocarpine for anticholinergic adverse effects associated with desipramine treatment.
Topics: Antidepressive Agents, Tricyclic; Constipation; Depressive Disorder; Desipramine; Humans; Male; Midd | 1996 |
Alterations in the secretory response of non-obese diabetic (NOD) mice to muscarinic receptor stimulation.
Topics: Animals; Autoantibodies; Base Sequence; Carbachol; Cyclic AMP; Diabetes Mellitus, Type 1; Mice; Mice | 1996 |
Serum pilocarpine esterase activity and response to oral pilocarpine.
Topics: Adult; Carboxylic Ester Hydrolases; Female; Humans; Kidney; Liver; Male; Pilocarpine; Xerostomia | 1996 |
Severity of xerostomia reduced when Salagen tablets taken during radiation therapy.
Topics: Drug Administration Schedule; Head and Neck Neoplasms; Humans; Pilocarpine; Radiation Injuries; Sali | 1996 |
Fluoride and pilocarpine reduce the risk of caries produced by chronic clomipramine treatment in rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Cariostatic Agents; Cholinergic Antagonists; Cl | 1997 |
[Preparation and evaluation of solid dispersions of pilocarpine hydrochloride for alleviation of xerostomia].
Topics: Cellulose; Delayed-Action Preparations; Dosage Forms; Humans; Hypromellose Derivatives; Male; Methyl | 1997 |
Re: Researchers make slow headway in managing dry mouth.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Lymphoma; Parasympathomimetics; Pilocarpine; | 1997 |
Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Parasympathomimetics; Pilocarpi | 1997 |
Care of psychiatric patients.
Topics: Cholinergic Antagonists; Humans; Mental Disorders; Parasympathomimetics; Pilocarpine; Xerostomia | 1998 |
The use of pilocarpine hydrochloride to prevent xerostomia in a child treated with high dose radiotherapy for nasopharynx carcinoma.
Topics: Child; Humans; Male; Miotics; Nasopharyngeal Neoplasms; Pilocarpine; Radiotherapy; Xerostomia | 1998 |
ACR presentations support Salagen tablets as a safe and effective treatment for the dry mouth symptoms caused by Sjögren's syndrome.
Topics: Humans; Parasympathomimetics; Pilocarpine; Sjogren's Syndrome; Xerostomia | 1999 |
Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?
Topics: Administration, Oral; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middl | 1999 |
Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study.
Topics: Adult; Candida albicans; Colony Count, Microbial; Female; Humans; Middle Aged; Parasympathomimetics; | 1998 |
Artificial saliva versus pilocarpine for xerostomia.
Topics: Data Collection; Humans; Parasympathomimetics; Pilocarpine; Saliva, Artificial; Xerostomia | 1999 |
Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment.
Topics: Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Parasympatho | 1999 |
Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Chronic Disease; Female; Graft vs Host Disease; Huma | 1999 |
Xerostomia. Absence makes the mouth get drier.
Topics: Aged; Humans; Muscarinic Agonists; Pilocarpine; Saliva; Saliva, Artificial; Xerostomia | 2000 |
Cevimeline (Evoxac) for dry mouth.
Topics: Acetylcholine; Clinical Trials as Topic; Contraindications; Humans; Intestinal Absorption; Muscarini | 2000 |
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.
Topics: Animals; Anti-Bacterial Agents; Atropine; Biopsy; Cat Diseases; Cats; Clindamycin; Cornea; Deglutiti | 2001 |
The use of pilocarpine in opioid-induced xerostomia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Narcotics; Neopl | 2000 |
The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease.
Topics: Administration, Oral; Albumins; Calcium; Chronic Disease; Epidermal Growth Factor; Graft vs Host Dis | 2001 |
A new medication for treatment of dry mouth in Sjögren's syndrome.
Topics: Contraindications; Humans; Muscarinic Agonists; Pilocarpine; Quinuclidines; Receptors, Muscarinic; S | 2001 |
Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats.
Topics: Animals; Male; Muscarinic Agonists; Pilocarpine; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; S | 2001 |
Pilocarpine treatment of xerostomia in head and neck patients.
Topics: Female; Head and Neck Neoplasms; Humans; Male; Muscarinic Agonists; Pilocarpine; Radiotherapy; Saliv | 2002 |
Salivary enhancement: current status and future therapies.
Topics: Animals; Aquaporin 1; Aquaporins; Blood Group Antigens; Cholinergic Agents; Cranial Irradiation; Den | 2001 |
Assessing salivary gland hypofunction--Part two.
Topics: Anti-Infective Agents, Local; Candidiasis, Oral; Dental Caries; Humans; Maltose; Mastication; Muscar | 2002 |
[Measurement by means of 99mTc-pertechnetate of the function of salivary glands before and after stimulation with pilocarpine in cases of sicca-syndrome of the parotidic glands (author's transl)].
Topics: Adult; Aged; Carbachol; Female; Humans; Hypopharynx; Male; Middle Aged; Parotid Gland; Pharyngeal Ne | 1979 |
Rampant dental caries in the treatment of depression.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Dental Caries; Depression; Drug Combinations | 1978 |
Salivary flow induction by buccal permucosal pilocarpine in anesthetized beagle dogs.
Topics: Administration, Buccal; Animals; Biological Availability; Dogs; Female; Hydrogen-Ion Concentration; | 1992 |
Pilocarpine disposition and salivary flow responses following intravenous administration to dogs.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Dose-Response Relationship, Drug; Female; Infus | 1992 |
Salivary secretion and denture retention.
Topics: Aged; Alveolar Bone Loss; Denture Retention; Denture, Complete; Denture, Complete, Lower; Denture, C | 1992 |
Treatment for radiation-induced xerostomia. An innovative remedy.
Topics: Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Male; Oils; Pilocarpine; Radiother | 1992 |
[Analysis of the effectiveness of pilocarpine in the management of xerostomia].
Topics: Amylases; Humans; Pilocarpine; Saliva; Xerostomia | 1990 |
Pilocarpine oral solution.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pilocarpine | 1991 |
Drug-induced xerostomia.
Topics: Adolescent; Aged; Aging; Female; Humans; Male; Middle Aged; Pilocarpine; Saliva, Artificial; Xerosto | 1991 |
Oral complications of cancer therapies. Management of salivary dysfunction.
Topics: Head and Neck Neoplasms; Humans; Pilocarpine; Radiotherapy; Xerostomia | 1990 |
Scintigraphy of the salivary glands in Sjögen's syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Middle Aged; Parotid Gland; | 1987 |
Treatment of xerostomia.
Topics: Humans; Pilocarpine; Saliva, Artificial; Xerostomia | 1988 |
Systemic therapy of salivary gland hypofunction.
Topics: Anethole Trithione; Bromhexine; Humans; Pilocarpine; Salivary Gland Diseases; Salivary Glands; Xeros | 1987 |
[Treatment of xerostomia with pilocarpine. Based on l5 years' experience and treatment of 500 patients].
Topics: Humans; Pilocarpine; Salivary Gland Diseases; Sjogren's Syndrome; Xerostomia | 1985 |
Pilocarpine used to stimulate normal saliva production.
Topics: Humans; Pilocarpine; Salivary Glands; Salivation; Xerostomia | 1985 |
[Xerostomia. II. Therapeutic possibilities].
Topics: Denture Design; Food; Humans; Mouthwashes; Neostigmine; Pilocarpine; Saliva, Artificial; Salivation; | 1985 |
[Radioisotope scanning of salivary glands in dry mouth].
Topics: Adult; Aged; Atropine; Biopsy; Female; Humans; Injections, Intramuscular; Injections, Intravenous; M | 1972 |
[Therapy of dryness of the mouth induced by psychopharmacological drugs].
Topics: Chewing Gum; Ergoloid Mesylates; Humans; Pilocarpine; Tranquilizing Agents; Xerostomia | 1969 |
Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan].
Topics: Animals; Atropine; Conditioning, Classical; Dogs; Electric Stimulation; Hexamethonium Compounds; Imi | 1969 |